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Synthetic polyester have received tremendous research interest in the past decades. Owing to its 
wide applications in degradable structure polymers and biomedical fields, there is an increasing 
need of smart materials that satisfy complex application requirements. The goal of my Ph.D. 
thesis is to expend the chemistry and materials of poly(α-hydroxyalkanoic acids) (PAHAs). In 
first part of this dissertation (chapter 2), we developed a metal catalyst based method for 
preparation of well-defined, side-chain and terminal modified poly(α-hydroxyalkanoic acids) 
from α-hydroxy acid O-carboxyanhydrides (OCA) monomers. Bon careful screening of ligand 
and initiator, (BDI)Zn-1 ((BDI-IE)Zn(OCH(CH3)COOCH3), (BDI-IE) = 2-((2,6-
diethylphenyl)amino)-4-((2,6-diisopropylphenyl)imino)-2-pentene)) were developed for the 
controlled ROP of OCAs with various side chains. This catalyst overcame the epimerization 
problem of conventional organocatalyst, produce highly isotactic PAHAs from chiral OCA 
monomers, enabled controlled copolymerization of OCAs and lactide, and facilitated the 
synthesis of block copolymers potentially useful for various biomedical applications. Preliminary 
mechanistic studies suggest that the monomer/dimer equilibrium of the zinc catalyst influence 
the ROP of OCAs, with the monomeric (BDI)Zn-1 possessing superior catalytic activity for the 
initiation of ROP in comparison to the dimeric (BDI)Zn complex. In my second part of work, I 
focused on developing side-chain modified PAHAs for drug delivery (chapter 3) and gene 
delivery (chapter 4) applications. In chapter 3, side chain introduced boronic acid was able to 
successfully tackle encapsulation challenge and formulated doxorubicin encapsulated micelles 
with high drug loading, quantitative loading efficiency, well-tuned drug release and potent 
antitumor efficacy. In chapter 4, PAHAs with side chain modified tertiary amine groups was 
utilized as efficient gene delivery vehicle and high transfection efficiency was achieved. Finally, 
in chapter 5, we developed a caged metabolic precursor responsive to DT-diaphorase in 
mammalian cells. The decaging process was finely tuned and trigger responsive cell surface 
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CHAPTER 1: INTRODUCTION 
1.1 Poly(α-hydroxyalkanoic acid) 
Poly(α-hydroxyalkanoic acid), or poly(α-hydroxy acid) (PAHA), is one of the most widely used 
degradable polymeric materials.1-4 PAHA has been applied in fields such as 3D printing,5-7 
sacrificial materials,8, 9 and degradable packaging.10-12 To add up, because of their 
biodegradability and biocompatibility,13 PAHAs have also been widely used for a variety of 
biomedical applications, including resorbable sutures,1, 14 implants,15, 16 drug delivery vehicles,2, 
17-19 and tissue engineering scaffolds.20 Common examples of PAHAs include poly(lactic acid) 
(PLA), poly(glycolic acid) (PGA), and poly(lactide-co-glycolide) (PLGA). They are readily 
prepared from either condensation reaction from corresponding α-hydroxy acids, or ring-opening 
polymerization of cyclic lactone monomers,21 naming lactide (LA) or glycolide (GA). PLA and 
PGA, the two most widely used materials of PAHA class, provided a relative wide range of 
tunability of its mechanical property, thermo-stability, and degradability. Specifically, due to the 
conformation alinement of methyl groups on PLA side chain, various PLA materials has been 
prepared with specific control of tacticity, or alinement of methyl groups along the polymer 
backbone. A range of metal based catalyst has been reported to polymerize lactide with retention 
of steric configuration,22 and also controlling the alinement of adjacent repeating units.23 A wide 
range of PLA, for example atactic PLA, isotactic PLA, syndisotactic PLA, and heterotactic PLA, 
has been prepared with their crystallinity, glass transition, mechanical strength, and degradation 
rate finely tuned.23-28 The incorporation of glycolide monomer into PLA chain provided 
accelerated hydrolysis rate, resulting in PLGA materials that meet multiple application need 
which desired degradation rate is achieved. 
Despite the fact that PAHA prepared from LA and GA showed good tunability in terms of its 
physical and chemical properties, there is an emerging challenge polymeric material face in 
biomedical applications. The material not only needs to have the right static characteristic, but 
also required to have the ability to adapt and respond to local environment, naming “smart” 
materials.29-33 Specifically, due to the inert nature of side chains of PLA and PGA, researchers 
developed new monomers with side chain functional group or reacting site to introduce extra 
properties to PAHA materials. Functional 1,4-dioxane-2,5-diones, lactide derivatives with 
methyl group substituted by other moieties, have been investigated as functional monomers to 
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synthesize PAHAs. However, this strategy is complicated by the moderate accessibility and poor 
reactivity in ring-opening polymerization,34-36 due to lack of ring-strain in these 6-member-ring 
lactone monomers. During last years, O-carboxyanhydrides (OCA) have emerged as suitable 
alternatives to 1,4-dioxane-2,5-diones for the efficient preparation of functionalized PAHA with 
high level of polymerization control and good side chain tolerance.37-39 
1.2 O-carboxyanhydride chemistry 
O-carboxyanhydride, or OCA, has general backbone structure of 1,3-dioxane-2,4-diones, with 
substitution group on 5- position.37, 38 OCAs are typically prepared via carbonylation of α-
hydroxyacids. Phosgene and its surrogates diphosgene and triphosgene are used as cabonylation 
agents.40-44 The OCA monomers are usually purified through either column chromatography or 
recrystallization. Of note, OCAs have significantly higher stability against hydrolysis as 
compared to N-carboxyanhydrides, which provides them extra promise as easy to handle 





48, 49 and L-lysine
44 have been developed previously. 
 
Scheme 1.1 Ring opening polymerization comparison of OCA and lactide 
OCA monomers, especially LacOCA, has been extensively studied as compared to its 6-member 
ring analog LA. From a model DFT study, the ring opening driving force of LacOCA is mainly 
contributed by two parts: enthalpic contribution from the ring-opening releasing ring-strain and 
entropic contribution from the decarboxylation step.50 As a result, LacOCA undergo ring 
opening polymerization under much milder condition under the catalysis of DMAP (room 
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temperature, several hours)40 as compared to lactide using same catalyst (several days with 
heat).51 DMAP also has been demonstrated to successfully promote the polymerization of other 
OCAs including L-(Bn)GluOCA, L-(alkynyl)TyrOCA, L-(Bn)SerOCA, L-PheOCA, L-
(Cbz)LysOCA, using primary alcohol or secondary alcohol as initiators.41, 43, 44, 47, 49 The 
resulting PAHAs have narrow PDI and finely tuned molecular weight (Mn). Meanwhile, not all 
OCAs showed similar level of polymerization control using DMAP. For example, L-ManOCA 
displayed significant epimerization of sterogenic carbon under the catalysis of DMAP and 
resulting polymer exhibited poor Mn control as well as significant level of side reaction.
36, 46 This 
behavior was attributed to the basicity of DMAP and the increased acidity of methine proton on 
α-position. Much better polymerization results were obtained by using the ion pair formed by 
combination of pyridine with equal molar amount of mandelic acid.46 Other organocatalyst such 
as NHC have also been investigated over the recent years and achieved some success in 
polymerizing OCA monomers.39, 52-55 
As mentioned in previous section, PAHAs has been extensively used in biomedical application, 
especially nanomedicine.2, 56-64 Compared with traditionally used PAHAs such as PLA and 
PLGA, PAHAs prepared from OCA monomers have tremendous tunability in their 
physicochemical properties, including hydrophobicity/hydrophilicity, crystallinity, and 
degradation kinetics. Our group previously improved our drug-PLA NPs system by introducing 
enhanced hydrophobicity on PLA side chains. Specifically, L-PheOCA was used as building 
block for the drug-PAHA conjugates, termed CPT-pPheLA. Micelle NP prepared from CPT-
pPheLA has 50% lower critical micelle concentration value (0.022 mg/mL vs 0.045 mg/mL),43 
with enhanced stability upon dilution. We also developed core-cross-linked (CCL) micelles that 
undergo disassembly and concurrent drug release upon redox triggering. L-(Alkynyl)TyrOCA 
was utilized to introduce side chain alkynyl groups that were crosslinked through copper 
catalyzed Click reaction with di-functioned azido crosslinker.48 The crosslinker bearing disulfide 
linkage was cleaved by intracellular GSH and resulting in disassembly of micelle and release of 






1.3 Scope and organization 
 
Scheme 1.2 Organization of the dissertation 
Scheme 1.2 depicts the organization and flow of my thesis. The aim of my Ph.D. thesis is to 
further develop OCA based PAHA material as promising platform to tackle challenges faced in 
biomedical applications. In chapter 2, my thesis research started with developing a unique OCA 
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polymerization method through β-diiminate zinc catalyst. I conducted the first systematic 
demonstration of controlled ring-opening polymerization method of OCAs based on metal 
catalyst. The co-polymerization of OCAs with LA was also demonstrated in chapter 2. The 
structure-property correlation of BDI-Zn catalyst system as well as the mechanistic aspect of it 
was studied.  Based on careful designed experiments, the active species and mechanistic 
correlation of BDI-Zn catalyst behavior with ligand steric hindrance and initiator structure was 
illustrated. The research focus was then shifted to the materials aspect of functional PAHAs. In 
chapter 3, I developed a donor-acceptor facilitated high drug loading system based on PAHAs. 
The side chain boronic acid functional group was able to stabilize and preventing loaded drug 
from aggregating. As a result, micelles with ultrahigh drug loading (>30 %), quantitative 
encapsulation efficiency, desired fast release, stability in physiological condition, and optimal 
anticancer potency were developed. In chapter 4, I developed cationic PAHAs which efficiently 
encapsulate plasmid DNA and transfected mammalian cells. The focused screening resulted a 
PAHA, PAPHP-1, which exhibited superior transfection efficiency compared to 
Lipofectamine™ 2000. To further expand the drug delivery potential of PAHAs, I also studied 
unnatural sugar based cancer labeling technique to address cancer targeting issue in chapter 5. I 
developed a promising platform to incorporate enzyme triggers onto azido bearing hexose and 
demonstrated DT-diaphorase responsive cell metabolic labeling as proof of concept.  
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CHAPTER 2: β-DIIMINATE ZINC CATALYZED POLYMERIZATION OF O-
CARBOXYANHYDRIDES* 
2.1 Introduction 
Poly(α-hydroxy acids) (PAHAs), including polylactide (PLA), are an important class of 
polymers that can be used in many applications ranging from biomedical devices to packaging 
materials.1, 2 These polymers are traditionally synthesized through the ring-opening 
polymerization (ROP) of lactones such as lactide (LA) or glycolide. Most PAHAs, however, lack 
side chain functionality, which prevents facile side-chain modification, limiting subsequent 
applications. While these issues can be addressed through the ROP of functional LA derivatives, 
such as hydroxyl-3 and norbornene-lactide,4 these monomers require multi-step synthesis, and 
the ROP lacks control.5, 6 Over the last ten years, O-carboxyanhydrides (OCAs) have emerged as 
an alternative class of highly active monomers for the synthesis of PAHAs that are readily 
available from amino acid precursors which inherently possess rich side chain functionality,7 
including aromatic rings,8 carboxylic acids,9, 10 alcohols,11 phenols,12, 13 and amines.14 OCAs thus 
provide significant potential for building complex PAHA structures for various applications 
including drug delivery,8, 13, 15 gene delivery12 and tissue engineering.11 
OCAs are mostly polymerized using pyridine based organocatalysts, such as 
dimethylaminopyridine (DMAP), into the corresponding PAHAs through a non-covalent 
basic/alcohol activation mechanism (Scheme 2.1). One drawback of these base catalysts is 
deprotonation of the α-methine hydrogen of OCAs during the ROP process.11, 16 This results in 
epimerization of the -carbon, and loss of stereoregularity in the PAHA backbone, which leads 
to changes in the properties of the final polymers.17, 18 It is therefore crucial to develop a viable 
catalyst that has enhanced control over the ROP of OCAs leading to PAHAs with controlled 
molecular weights (MWs) and stereoregularity. An alternative to the use of organocatalysts for 
the ROP of OCAs involves the use of organometallic catalysts,8, 19, 20 such as metal alkoxides 
that have been shown to polymerize lactones in a living, highly controlled manner.21, 22 In this 
                                                 
* Part of this chapter is adapted from the publication: Wang, R.; Zhang, J.; Yin, Q.; Xu, Y.; Cheng, J.*; Tong, R.*, 
“Controlled Ring-Opening Polymerization of O-Carboxyanhydrides Using β-Diiminate Zinc Catalyst.” Angew. 
Chem. Int. Ed. 2016, 55, 13010-13014 
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section, single-site organometallic catalyst ((BDI-IE)Zn(OCH(CH3)COOCH3), (BDI)Zn-1) is 
demonstrated as highly controlled catalyst for ROP of OCAs. 
 
Scheme 2.1 Mechanism of DMAP catalyzed OCA polymerization. Path A represent the non-
covalent basic/alcohol activation mechanism. 
Metal catalysts have been extensively studied in the field of ROP of cyclic lactones to build 
polyesters, especially for PLA.21-23 But to our best knowledge, no metal catalyst system has been 
reported to polymerize OCAs in well-controlled fashion. The first report dealing with metallic 
promoter for OCA polymerization dates back to 2011.20  Cobalt-salen complexes bearing 
nitrophenoxide coligands were evaluated as catalyst/initiator for ring-opening polymerization of 
LacOCA.20 The Mn of resulting PLA has lower than expected value, and it does not depend on 
the presence of an external alcohol initiator. Tin benzoate and tin octanoate, which is the most 
most frequent ROP catalyst for lactide, have also been evaluated in the LacOCA ring-opening 
polymerization.19, 20 Although PLA can be prepared using these metal carboxylates under heat, 
the lack of Mn control upon addition of 
iPrOH indicates again poorly defined polymerization 
behavior.  
Single-site transition metal catalysts (LnMR) have been regarded as one of the most promising 
catalyst system for ROP of cyclic lactones. The general formula of single-site catalyst LnMR 
demonstrates the mode of activity, where Ln is the ligand that remains attached to the metal 
center and modifies its activity; and R is the group that initiate the polymerization. Through 
careful tuning of ligand and initiator structure, homogeneous catalysts has been developed for 
various polymerization, achieving molecular weight control, PDI control, comonomer 
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incorporation and stereochemistry control.22, 24-32 Among them, β-diiminate zinc alkoxide 
((BDI)ZnOR) has been reported to polymerize lactide in living, well-controlled manner22. The 
coordination-insertion mechanism provides well-defined active ends for building PLAs with 
different stereo control21. BDIZn system has also been reported to be able to catalyze the ROP of 
β-butyrolactone, β-valerolactone33 and alternating polymerization of epoxides and CO2
34, 35. In 
the later part of this chapter, I looked into details of the mechanism of BDI-Zn catalyzed OCA 
polymerization as well as ligand and initiator design criteria. The mechanistic understanding of 
this system will also be illustrated in this section. 
2.2 Controlled ring-opening polymerization of O-carboxyanhydride 
 
Scheme 2.2 ROP of OCA monomers catalyzed by (BDI)Zn-1 
We used 1 as a model monomer (Scheme 2.2), which was conveniently prepared from L-
phenylalanine via a simple two-step synthesis.8 Because of the excellent control of lactone-type 
of monomer polymerization by Coates catalysts,22, 36 we prepared a number of Zn catalysts with 
varying degrees of bulkiness in the ancillary ligand or initiating alkoxide groups (Figure 2.1) and 
found that (BDI)Zn-1 provided exceptional polymerization results, outperforming the other 
(BDI)Zn catalysts tested. (BDI)Zn-1 contains a bulky asymmetric BDI ligand, and a (-)-methyl 
lactate moiety as the initiating group. The polymerization initiated by (BDI)Zn-1 in anhydrous 
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THF at room temperature was highly active; immediate gas generation was observed when 1 was 
added into the solution of (BDI)Zn-1 at different monomer-to-initiator ratios ranging from 25 to 
200 (Table 2.1, entries 1-4). Consumption of monomers for all reactions was complete within 5 
minutes as determined by the disappearance of the 1812 cm-1 anhydride peak by FT-IR. Analysis 
via gel permeation chromatography (GPC) of polymers resulting from 1 showed narrow 
polydispersity (PDI<1.1) with number-average molecular weights (Mn) close to the expected Mn, 
suggesting a highly controlled ROP process (Figure 2.2). The matrix-assisted laser 
desorption/ionization mass spectra (MALDI-MS) of poly(1) revealed methyl lactate as the end 
group (Figure 2.3), suggesting the initiation from (BDI)Zn-1. 
 
 






1 (BDI)Zn-1 50 0.5 >98 8.3 7.5 1.05 
2 (BDI)Zn-2 50 24 >98 21.4 7.5 1.33 
3 (BDI)Zn-3 50 0.5 >98 14.4 7.5 1.21 
4 (BDI)Zn-4 50 0.5 >98 9.9 7.5 1.58 
aDetermined by FT-IR measurement of peak intensity at 1812 cm-1 correspond to carbonyl 
groups in OCA ring. bDetermined by GPC analysis in DMF (0.1 M LiBr) using dn/dc = 0.103. 
cCalculated according to the feeding ratio of monomer to initiator.  




Table 2.1 Controlled ROP of OCAs mediated by (BDI)Zn-1[a]  





1 1 25 3.7 3.8 1.06 
2 1 50 8.3 7.5 1.05 
3 1 100 16.4 14.9 1.07 
4 1 200 33.1 29.7 1.02 
5 2 50 4.6 3.7 1.15 
6 3 50 7.9 9.0 1.15 
7 4 50 8.0 6.8 1.17 
8 5 100 26.5 20.4 1.29 
[a]Representative results of homopolymers initiated by (BDI)Zn-1 (2 mM) in THF at room 
temperature. Abbreviations: Mn (exp.): experimental number-average molecular weight; Mn 
(cal.): calculated molecular weight according to the feeding ratio between the monomer and 
(BDI)Zn-1; PDI: polydispersity index. 
We then expanded the monomer scope to other OCAs with various side chains, including methyl 
(L-LacOCA, 2), benzyl protected hydroxyl (L-Ser(Bn)OCA, 3), phenyl (L-ManOCA, 4), and allyl 
groups (L-Tyr(allyl)OCA, 5, Scheme 2.2). Under similar polymerization conditions, (BDI)Zn-1 
was able to initiate and polymerize all four OCAs. The GPC analysis of those PAHAs showed 
excellent polymerization control, similar to poly(1) and the Mn of the resulting polymers matched 




Figure 2.2 GPC traces of Entry 1-4 in Table 2.1 
 
Figure 2.3 MALDI-TOF spectrum of poly(PheOCA) prepared with (BDI)Zn-1. Calculated m/z 
= 104.05+22.99+148.05*n. The extra set of peak (e.g. m/z = 2423) attributes to poly(PheOCA) 





2.3 Copolymerization of O-carboxyanhydride and lactide 
Table 2.2 Controlled ROP of OCAs mediated by (BDI)Zn-1[a]  





1 1/2 50/50 10.9 11.1 1.10 
2 1/3 50/50 16.1 16.4 1.09 
3 2/3 50/50 16.5 12.6 1.10 
[a]Representative results of block-copolymers initiated by (BDI)Zn-1 (2 mM) in THF at room 
temperature. Abbreviations: Mn (exp.): experimental number-average molecular weight; Mn 
(cal.): calculated molecular weight according to the feeding ratio between the monomer and 
(BDI)Zn-1; PDI: polydispersity index. 
We also synthesized diblock-copolymers from two different OCAs (Table 2.2, entries 1-3). 
These block copolymers had remarkable control of MWs and MWDs (PDI < 1.1) like 
demonstrated in section 2.2. It is worth noting that benefited from the fast polymerization 
kinetics (studied in section 3), each portion of OCA monomer could be added 5 min after 
previous portion, which is easy to handle. 
We then explored if two types of monomers, LA and OCA, could be combined in single catalytic 
system to build block-copolymers (Table 2.3). As (BDI)Zn-alkoxides – structural analogs of 
(BDI)Zn-1 – are known to polymerize LA,22 we hypothesized that (BDI)Zn-1 might also achieve 
the block copolymerization of both LA and OCA. Of note, DMAP only polymerizes LA at high 
concentration and is difficult to achieve full conversion,37 disqualifying it as a suitable catalyst 
for one-pot ROP of LA and OCAs. We first constructed a poly(1) block with a degree of 
polymerization (DP) of 50 in the presence of (BDI)Zn-1. Upon full conversion of OCA 
(determined by FT-IR), L-lactide (LLA, 50 equiv. to (BDI)Zn-1) was added into the reaction 
mixture. LLA was fully converted within 4 h, confirmed by FTIR as the peak shift from 1750 
cm-1 (lactone) to 1760 cm-1 (ester). The resulting poly(1-b-LLA) block copolymer showed a 
monomodal peak with a PDI of 1.03, which completely shifted from 6.9 kDa to 17.4 kDa 
compared to that of poly(1)50 in GPC spectra; the Mn of the copolymer agreed well with the 
calculated value (Table 2.3, entries 1-2). We also realized identical control upon reversal of the 
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sequence of monomer addition (Table 2.3, entry 3), as the resulting poly(LLA-b-1) showed a 
monomodal peak with narrow MWD in the GPC (Figure 2.4) that agreeably overlapped with that 
of poly(1-b-LLA) (Figure 2.4). Additionally, a triblock copolymer poly(1-b-LLA-b-1) was 
synthesized by adding another potion of 1 (100 equiv. to initiator) into the poly(1-b-LLA) 
reaction solution (Table 2.3, entry 4). The obtained triblock copolymer exhibited controlled Mn 
of 32.3 kDa with the low PDI of 1.05, similar to that of diblock copolymer synthesis (Figure 
2.4), which suggests minimal transesterification reactions. Thus the chain ends of poly(1) or 
PLLA are capable of initiating the ROP of the other monomer. It is likely that the ROP of OCAs 
catalyzed by (BDI)Zn-1 shares the same active chain propagation group as the reported ROP of 
LA by Zn catalyst, presumably (BDI)Zn-alkoxide. 
Table 2.3 Block copolymerization of OCA (1) and LLA catalyzed by (BDI)Zn-1[a] 
 







1 1 50 6.9 7.5 1.07 
2 1/LLA 50/50 17.4 14.7 1.03 
3 LLA/1 50/50 13.4 14.7 1.03 
4 1/LLA/1 50/50/100 32.3 29.4 1.05 
[a]Representative results of block copolymers initiated by (BDI)Zn-1 (3.0 mM) in THF at 
room temperature; monomers were added sequentially. [b](BDI)Zn-1 was set as 1 equiv. 
relative to all of the monomer ratios. [c]Determined by GPC analysis in DMF (0.1 M LiBr) 




Figure 2.4 Normalized light scattering GPC traces of the block copolymers synthesized in Table 
2.3. 
Table 2.4 Dn/dc values for all homopolymers and block-copolymers calculated using 100% 
mass recovery methods from peaks. 
Homopolymers Block-copolymers 
monomer dn/dc polymer structure dn/dc 
1 0.103 150-b-250 0.073 
2 0.025 150-b-350 0.091 
3 0.093 250-b-350 0.058 
4 0.095 150-b-LA50 0.068 
5 0.105 LA50-b-150 0.069 
- - 150-b-LA50-b-1100 0.090 
 
In conclusion, in this section we described a highly reactive single-site catalyst, (BDI)Zn-1, for 
the controlled ROP of OCAs. The use of (BDI)Zn-1 allows the synthesis of homo- and block co-
PAHAs from a variety of OCA monomers, with controlled MW, narrow MWD, retained 
stereoregularity and no transesterification. One-pot block copolymerization of LA and OCAs can 
be easily accomplished with the use of (BDI)Zn-1, regardless of the monomer addition sequence. 
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2.4 Catalyst screening and kinetic study 
 
Figure 2.5 Kinetic study of the polymerization of 1 initiated by (BDI)Zn-1. (a) Plot of the Mn 
and PDI of poly(1) versus the monomer conversion. ([1] = 30 mM, [(BDI)Zn-1] = 0.10 mM). (b) 
First-order kinetic plot of the polymerization of 1. ([1] = 40 mM, [(BDI)Zn-1] = 0.17, 0.33, 0.50, 
0.67 mM, i.e., [1]/[(BDI)Zn-1] = 240, 120, 80, 60). 
To further elucidate the OCA ROP mechanism initiated by (BDI)Zn-1, we first conducted 
several kinetic studies to establish reaction orders of the OCA monomer and (BDI)Zn-1. The 
conversion of L-PheOCA (1, [1] was 40 mM initially) was monitored by FT-IR at different 
catalyst concentrations at room temperature ([(BDI)Zn-1] = 0.17-0.67 mM), and corresponding 
Mn values were obtained from GPC analysis. Because of the fast polymerization kinetics, we did 
a preliminary screening using various reagent to quench the polymerization process. We found 
that by adding excess amount of acetic acid, the polymerization process could be quenched while 
OCA was not further consumed by the quenching agent, enabling the quantification through FI-
IR measurement. The Mn of resulting poly(1) showed a linear correlation with the conversion of 
1, agreeing with the expected values (Figure 2.5-a). The PDI remained lower than 1.1 throughout 
the polymerization process. The polymerization proceeded with first-order dependence on OCA 
concentration (Figure 2.5-b), indicated by the linear relationship between –ln ([1]/[1]0) and 
reaction time. Derived from the kinetic data of four different concentrations of (BDI)Zn-1, the 
order in Zn catalyst concentration was determined to be 1.21 from the slope of the fitted lines 
(Figure 2.6), indicating that the ROP of 1 likely proceeds through monometallic enchainment 
step.33 These data, along with fair agreement between the observed and theoretical values of Mn 
and the MALDI results in Figure 2.3, strongly suggest that (BDI)Zn-1 acts as a single-site 
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catalyst wherein the bulky BDI ligand remains bound to the Zn center and the methyl lactate 
moiety initiates the polymerization. 
 
Figure 2.6 Plot of -ln(kapp) versus –ln[Zn] for ROP of L-PheOCA prepared with (BDI)Zn-1. The 
reaction order for zinc catalyst is 1.21 from slope of the plot. 
 
2.5 Dimer-monomer equilibrium of zinc catalysts 
As previously mentioned, the ligand (Ln) structure and the initiator (R) structure has profound 
effect on the catalytic behavior of single site metal catalyst. We prepared a number of Zn 
catalysts with varying degrees of bulkiness in the ancillary ligand or initiating alkoxide groups 
(Table 2.5) and found that (BDI)Zn-1 provided exceptional polymerization results, 
outperforming the other (BDI)Zn catalysts tested. 
(BDI)Zn-1 contains a bulky asymmetric BDI ligand, and a (-)-methyl lactate moiety as the 
initiating group. As a comparison, (BDI)Zn-2 with identical ligand but less steric hindered 
initiator (iPrOH) showed much slower polymerization kinetics, with three times higher obtained 
Mn value as compared to designed ones. (BDI)Zn-3, which has the same initiating groups as 
compared to (BDI)Zn-1 but more bulky BDI ligand, resulted in fast polymerization result but the 
Mn value was also twice as compared to feed ratio of monomer and initiator. Lastly, (BDI)Zn-4, 
which consisted more hindered BDI ligand and less hindered initiator, actually showed similar 
level of polymerization control compared to (BDI)Zn-1. When we compared the four GPC trace 
















of obtained PAHA from these four catalyst, the difference in polymerization behavior could be 
concluded as following: (BDI)Zn-1 catalyzed OCA ROP showed fast kinetics, controlled Mn, 
monomodal distribution in GPC traces; (BDI)Zn-2 catalyzed OCA ROP showed slow kinetics, 
uncontrolled Mn, monomodal distribution in GPC traces; (BDI)Zn-3 catalyzed OCA ROP 
showed fast kinetics, uncontrolled Mn, bimodal distribution in GPC traces with shoulder peak on 
higher molecular weight side; (BDI)Zn-4 catalyzed OCA ROP showed fast kinetics, controlled 
Mn, bimodal distribution in GPC traces with shoulder peak on higher molecular weight side. The 
shoulder peak from (BDI)Zn-3 and (BDI)Zn-4 could be attributed to the mismatch of steric 
hindrance of BDI ligand with OCA side chain and will be studied in future works. 
Table 2.5 Catalyst screening of various (BDI)Zn catalysts for the ROP of 1. 
 






1 (BDI)Zn-1 50 0.5 >98 8.3 7.5 1.05 
2 (BDI)Zn-2 50 24 >98 21.4 7.5 1.33 
3 (BDI)Zn-3 50 0.5 >98 14.4 7.5 1.21 
4 (BDI)Zn-4 50 0.5 >98 9.9 7.5 1.58 
aDetermined by FT-IR measurement of peak intensity at 1812 cm-1 correspond to carbonyl 
groups in OCA ring. bDetermined by GPC analysis in DMF (0.1 M LiBr) using dn/dc = 0.103. 
cCalculated according to the feeding ratio of monomer to initiator.  
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Figure 2.7 GPC traces of Poly(PheOCA) obtained from the four BDI-Zn catalysts. 
We tried to rationale the polymerization behavior of these four different catalysts. (BDI)Zn 
catalysts were reported to have monomer-dimer equilibria in solution,33 which significantly 
affect the catalytic activity of (BDI)Zn catalysts in the lactone’s ROP. We investigated whether 
such equilibria could also influence the ROP process of OCAs. (BDI)Zn-1 showed a single set of 
ligand peaks in 1H NMR spectra (Figure 2.8), indicating a predominant monomeric form in THF 
solution (less than 5% of dimeric form). As a comparison (BDI)Zn-2 showed two sets of peaks 
for ethyl and isopropyl groups on the BDI ligand in 1H NMR spectra (Figure 2.9), indicating a 
predominant dimeric form in THF solution (about 5% of monomeric form calculated based on 
the integration of the singlet peak at δ 4.9 ppm).34 We observed slower kinetics of OCA 1 
polymerization initiated by (BDI)Zn-2 compared with that of (BDI)Zn-1 under the same 
conditions ([1]/[Zn] = 50:1, [Zn] = 1.0 mM). While only 60% of 1 was consumed within 4 hours 
in the presence of (BDI)Zn-2 (being eventually consumed at 24 h), the rapid ROP of 1 mediated 
by (BDI)Zn-1 was completed in seconds. The resulting polymer had three times higher Mn than 
expected value and a high PDI value of 1.33 (Figure 2.10). The MALDI-MS analysis indicated 
that all of poly(1) had the isopropanol group from (BDI)Zn-2. As (BDI)Zn-1 and (BDI)Zn-2 
share the same ligand, the chain propagating species should be identical. In other words, the high 
MW of poly(1) catalyzed by (BDI)Zn-2 was not due to the transesterification. The drastic 
difference in catalytic behavior likely comes from the initiation step. We thus studied the 
initiation step of the ROP catalyzed by (BDI)Zn-2 by mixing (BDI)Zn-2 and OCA 1 at 1:1 ratio. 
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The 1H NMR spectrum of the reaction mixture at 4 hours exhibited a distinct quartet peak at δ 
5.25 ppm (α-methine hydrogen in poly(1)), indicating the formation of long isotactic poly(1) 
instead of the theoretical (BDI)Zn-(OCH(Ph)CO)-OiPr complex (Figure 2.11). On the contrast, 
mixing (BDI)Zn-1 and OCA 1 at 1:1 ratio resulted in the 1:1 adduct (the distinguishable quartet 
peak of α-methine proton at 5.32 ppm) with only a small portion of oligomers (< 20% based on 
NMR, Figure 2.12). These results suggest that the dimeric (BDI)Zn-2 complex likely inhibits the 
coordination of 1 and prevents initiation of the ROP; only a small portion of monomeric 
(BDI)Zn complex in (BDI)Zn-2 served as the actual initiating species for the ROP (Scheme 2.3). 
A similar phenomenon is observed in the ROP of β-butyrolactone in which the dimeric (BDI)Zn-
alkoxide complex is a poor catalyst for ROP.33  
 




Figure 2.9 1H NMR spectrum of (BDI)Zn-2 (500 MHz, d8-THF, x-axis: δ ppm). Two sets of 
peaks attributed to dimeric form of (BDI)Zn-2, the ratio of dimeric form and monomeric form 
calculated from integral of peak a and a’. 
 
Figure 2.10 Results of ROP of L-PheOCA prepared with (BDI)Zn-2. aDetermined by FT-IR 
measurement of peak intensity at 1812 cm-1 correspond to carbonyl groups in OCA rings. 
bDetermined by GPC-RI analysis in DMF (0.1 M LiBr) cCalculated according to the feeding 





Figure 2.11 1H NMR spectrum of mixing 1:1 equivalent of (BDI)Zn-2 and PheOCA for 4 h (500 
MHz, d8-THF, x-axis: δ ppm). The quartet peak at 5.25 ppm indicated long isotactic PAHA 
formation. 
 
Figure 2.12 1H NMR spectrum of mixing 1:1 equivalent of (BDI)Zn-1 and L-PheOCA for 10 




Scheme 2.3 The structural difference between (BDI)Zn-1 and (BDI)Zn-2. 
Combining results from both kinetics and initiation studies, we thus propose a polymerization 
mechanism of ROP of OCA catalyzed by (BDI)Zn-1 (Figure 2.13). The ROP process starts with 
the coordination of the OCA monomer to the Zn center of the monometallic (BDI)Zn-1 complex. 
Subsequent ring-opening occurs with acyl-oxygen bond cleavage and the removal of CO2, 
maintaining the configuration at the α-methine carbon. The active monometallic (BDI)Zn resides 
at the chain end and mediates the monomer insertion and chain propagation. 
 





2.6 In situ formed BDI-Zn catalyst for ROP of OCA 
As (BDI)Zn-1 has protic initiator attached to the metal center prior to the polymerization, there is 
little tuning space in terms of the end structure of PAHAs synthesized from this method. We 
were interested in developing a method to synthesize PAHA of controlled length from alcohols 
with different structures. This is of significant interest in developing drug-polymer conjugates.8, 
36 We reasoned that pre-mixing protic initiator with precursor of (BDI)Zn catalyst, 
(BDI)ZnN(TMS)2, would result in situ formed catalyst which persist the excellent catalytic 
towards ROP of OCAs. There are two things need to demonstrate: Firstly, the exchange between 
precursor and protic initiator should be finished in relative timely fashion; secondly, the released 
side product of HMDS from reacting (BDI)ZnN(TMS)2 with alcohol species should not interfere 
with the ROP process. 
 
Figure 2.14 NMR kinetic study of reacting BDI-Zn precursor with model alcohol, methyl lactate 
(MeLac) or methanol (MeOH). The study was performed in d8-THF at 10 mM. 
We first used NMR to track the reaction between (BDI)ZnN(TMS)2  and model alcohols, methyl 
lactate and methanol. We used the TMS peak to quantify conversion of (BDI)ZnN(TMS)2 
conversion. We choose two different BDI ligand, with slightly different steric hindrance. The 
two precursor, BDI-II and BDI-IE, reacted with methyl lactate and methanol with distinctly 
different kinetics (Figure 2.14). Methyl lactate reacted with BDI-IE within the first five minutes 
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of mixing, resulting in (BDI)Zn-1 which is the identical catalyst characterized in section 2.2 and 
2.3. As comparison, methyl lactate reacted with BDI-II, which was slightly more hindered, much 
slower, reaching >95% conversion after 5 h of mixing. Surprisingly, for methanol reacting with 
either BDI-II or BDI-IE, despite the minimal steric effect of methanol molecule, both reaction 
took place at much slower rate as compared to reacting methyl lactate with these catalyst 
precursors. Kinetic constant could be extracted from the kinetic plot: >2000 L/mol·min (BDI-IE 
+ MeLac), 8.85 L/mol·min (BDI-IE + MeOH), 3.80 L/mol·min (BDI-II + MeLac), 0.96 
L/mol·min (BDI-II + MeOH). It was cleared suggesting the important role the α-carbonyl group 
played in facilitating ligand exchange. 
Table 2.6 Representative polymer of (BDI)Zn-1 (entry 1-4) and in situ formed (BDI)Zn-1 (entry 
5-6) catalyzed ROP of L-PheOCA. 






1 25 : 1 0.5 >98 3.7 3.8 1.06 
2 50 : 1 0.5 >98 8.3 7.5 1.05 
3 100 : 1 0.5 >98 16.4 14.9 1.07 
4 200 : 1 0.5 >98 33.1 29.7 1.02 
5 50 : 1 0.5 >98 7.1 7.5 1.08 
6 100 : 1 0.5 >98 15.0 14.9 1.05 
aDetermined by FT-IR measurement of peak intensity at 1812 cm-1 correspond to carbonyl 
groups in OCA ring. bDetermined by GPC analysis in DMF (0.1 M LiBr) using dn/dc = 0.103. 
cCalculated according to the feeding ratio of monomer to initiator.  
We then studied the polymerization behavior of in situ formed (BDI)Zn-1 as compared to 
isolated catalyst (Table 2.6). From the polymerization results, in situ formed (BDI)Zn-1 had 
identical polymerization control and narrow PDI as compared to isolated form. These results 
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demonstrated the inert behavior of HMDS generated from the ligand exchange process and 
proved the in situ catalyst strategy was successful.  
 
2.7 Materials and methods 
Materials: ALL chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise noted. L-Lactide (LLA) was purchased from TCI America (Portland, OR, USA). It was 
recrystallized three times in toluene and stored at -30 oC in glove box. Anhydrous 
tetrahydrofuran (THF) was dried by an alumina column and stored in glove box. d8-THF, 
isopropanol, and L-methyl lactate were dried by 4Å molecular sieve to remove trace amount of 
water. L-PheOCA, L-LacOCA, L-Ser(Bn)OCA, L-ManOCA, L-Tyr(allyl)OCA were synthesized 
according to the literature. All OCAs were recrystallized three times and stored at -30 oC in 
glove box. (BDI)Zn catalysts and precursor were synthesized according to the previous report 
using similar procedure.  
Instrumentation: NMR spectra were recorded on Varian U500 (500 MHz), VXR-500 (500 
MHz), Varian U600 (600 MHz) spectrometers. Infrared spectra were recorded on a Perkin Elmer 
100 serial FT-IR spectrometer. Quantified FT-IR spectra were obtained using IR liquid 
transmission cell (Specac Inc., Swedesboro, NJ, USA). Gel permeation chromatography (GPC) 
experiments were performed on a system equipped with an isocratic pump (Model 1260, Agilent 
Technology, Santa Clara, CA, USA), a DAWN HELEOS multiangle laser light scattering 
(MALLS) detector, and an Optilab rEX refractive index detector (Wyatt Technology, Santa 
Barbara, CA, USA). The detection wavelength of HELEOS was set at 658 nm. Separations were 
performed using serially connected size exclusion columns (100 Å, 103 Å, 104 Å, 105  Å, and 
106  Å Phenogel columns, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, CA, USA) at 60 °C 
using DMF containing 0.1 M LiBr as the mobile phase.  The molecular weights of polymers 
were determined from the dn/dc value assuming 100% mass recovery using ASTRA software 
(Version 6.1.1, Wyatt Technology). MALDI-TOF spectra were taken on a Bruker Ultra 
Flextreme equipped with a 337 nm nitrogen laser. An accelerating voltage of 23 kV was applied, 
acquiring 1000 shots for each sample. Samples were prepared using trans-2-[3-(4-tert-
butylphenyl)-2-methyl-2-propenylidene]malonitrile (DCTB) as the matrix (10 mg mL-1 in THF), 
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and sodium trifluoroacetate as the cationization agent (10 mg mL-1 in THF). Samples were 
dissolved in THF (10 mg mL-1). Solutions of matrix, salt, and polymer were mixed in a volume 
ratio of 4 : 1 : 1, respectively. The mixed solutions (0.5 µL) were hand spotted on a stainless 
steel MALDI target and allowed to dry completely. All spectra were recorded in reflectron mode. 
General Polymerization Procedure using (BDI)Zn catalyst: In a glove box, (BDI)Zn catalyst 
(20 mM) and OCA (100 mM) were separately dissolved in anhydrous THF to obtain stock 
solution. (BDI)Zn solution (100 µL) was added into a 7-mL glass vial equipped with a magnetic 
stir bar and diluted with THF (1.0 mL). The OCA solution with pre-calculated concentration (1.0 
mL for [OCA]:[Zn] = 50) was added into catalyst solution under stirring. After reaction was 
complete, resulting polymers were precipitated in hexane and dried to give final product. Yields 
were typically >80%. Trace amount of BDI ligand was washed away through twice precipitation 
in ether. 
General Polymerization Procedure of DMAP/iPrOH: In a glove box, DMAP catalyst (20 
mM) iPrOH (20 mM), and OCA (100 mM) were separately dissolved in anhydrous THF to 
obtain stock solution. DMAP solution (100 µL) and iPrOH solution (100 µL) was added into a 7-
mL glass vial equipped with a magnetic stir bar and diluted with THF (1.0 mL). The OCA 
solution (1.0 mL for [M]:[I] = 50) was added into catalyst solution under stirring. After reaction 
was complete, resulting polymers were precipitated in hexane and dried to give final product. 
Yields were typically >80%.  
Poly(phenyllactic acid) (from L-PheOCA): 
1H NMR (500 MHz, CDCl3): δ 7.27 (m, 3H), 7.12 
(d, 2H, J = 7.0 Hz), 5.27 (dd, 1H, J = 8.0, 8.5 Hz), 3.19 (dd, 1H, J = 8.0, 15 Hz), 3.05 (dd, 1H, J 
= 8.5, 15 Hz). 13C NMR (125 MHz, CDCl3): δ 168.30, 135.63, 129.56, 128.73, 127.33, 73.46, 
37.11. 
Poly(lactic acid) (from L-LacOCA): 
1H NMR (500 MHz, CDCl3): δ 5.15 (q, 1H, J = 7.0 Hz), 
1.57 (d, 3H, J = 7.0 Hz). 13C NMR (125 MHz, CDCl3): δ 169.84, 69.24, 16.89. 
Poly(benzyloxylactic acid) (from L-Ser(Bn)OCA): 
1H NMR (500 MHz, CDCl3): δ 7.26 (m, 5H), 
5.46 (dd, 1H, J = 7.0 Hz), 4.53 (s, 2H), 3.95 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 166.72, 
137.72, 128.62, 127.98, 127.96, 73.65, 73.01, 68.73. 
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Poly(mandalic acid) (from L-ManOCA): 
1H NMR (500 MHz, CDCl3): δ 7.28 (m, 5H), 5.98 (s, 
1H). 13C NMR (125 MHz, CDCl3): δ 167.03, 132.56, 129.61, 128.91, 128.06, 75.00. 
Poly(4-allyloxylphenyllactic acid) (from L-Tyr(allyl)OCA): 
1H NMR (500 MHz, CDCl3): δ 
7.27 (m, 2H), 6.75 (m, 2H), 6.00 (m, 1H), 5.35 (d, 1H), 5.26 (d, 2H), 4.45 (t, 2H), 3.10 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ 168.41, 157.94, 133.57, 130.66, 127.82, 117.81, 114.95, 73.61, 
68.96, 36.34. 
Conversion of Monomer: For confirming fully conversion purpose, a small aliquot was 
removed from reaction mixture and dipped onto a KBr salt plate. Disappearance of peak at 1812 
cm-1 indicated fully consumption of OCA monomers. For quantification, an aliquot of the 
reaction mixture (100 µL) was quenched with 5% acetic acid THF solution (100 µL). OCA 
concentration was quantified by FT-IR using pre-calibrated standard curve at 1812 cm-1. 
General Procedure for the Block Copolymerization of OCAs: The (BDI)Zn-1 catalyst in THF 
solution (50 µL, 20 mM) was diluted in 500 µL THF.  L-PheOCA solution (0.5 mL, 19.2 mg/mL, 
100 mM) was added and stirred at room temperature for 10 min. The complete monomer 
consumption was confirmed by FT-IR. L-Ser(Bn)OCA solution (0.5 mL, 22.2 mg/mL. 100 mM) 
was then added to the reaction mixture. The reaction mixture was stirred for another 10 min. 
After the fully consumption of both OCAs, resulting polymer was precipitated in hexane, dried 
and subjected to further analysis. 
Procedure for the Block Copolymerization of L-PheOCA and L-lactide: The (BDI)Zn-1 in the 
THF solution (20 mM, 200 µL) was diluted in 100 µL THF. The L-PheOCA solution (1mL, 38 
mg/mL, 200 mM) was added and stirred at room temperature for 10 min. The complete 
monomer consumption was confirmed by FT-IR. The L-lactide solution (1mL, 29 mg/mL. 200 
mM) was then added to the reaction mixture. The reaction mixture was stirred for another 4 hour 
till the fully consumption of LLA. The resulting polymer was precipitated in hexane and dried to 
give final product.  
General Polymerization Procedure using in situ (BDI)Zn catalyst: In a glove box, 
(BDI)ZnN(TMS)2 catalyst precursor (20 mM),  methyl lactate (20 mM), and OCA (100 mM) 
were separately dissolved in anhydrous THF to obtain stock solution. (BDI)Zn solution (100 µL) 
was mixed with methyl lactate solution (100 µL) in a 7-mL glass vial equipped with a magnetic 
stir bar and stirred for 10 min for complete ligand exchange. The in situ catalyst solution was 
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diluted with 1 mL of THF. The OCA solution with pre-calculated concentration (1.0 mL for 
[OCA]:[Zn] = 50) was added into catalyst solution under stirring. After reaction was complete, 
resulting polymers were precipitated in hexane and dried to give final product. Yields were 
typically >80%. Trace amount of BDI ligand was washed away through twice precipitation in 
ether. 
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CHAPTER 3 DONOR-RECEPTOR COORDINATION FACILIATED POLYESTER 
MICELLE FOR DRUG DELIVERY 
 
3.1 Introduction 
Polymeric nanoparticle (NP) has been extensively studied as promising carrier for therapeutic 
cargos for cancer treatment.1-4 Benefited from enhanced permeation and retention effect (EPR), 
NPs with size smaller than 100 nm tend to accumulate in tumor tissue.5-7 As compared to small 
molecule therapeutics such as chemotherapy drugs, NPs with proper surface modification 
circulate longer in blood stream, resulting in elongated therapeutic windows as well.3, 8-15 The 
enhanced tumor accumulation of toxic chemotherapy drugs also greatly reduced their systematic 
toxicity, which is also one the major challenged chemotherapy faces.16-22 Polyester materials, 
specifically, has been widely used in this application benefited from their biocompatibility and 
biodegradability.23, 24 Despite all the promises NP provide to cancer treatment, clinical 
translation of such systems still face challenges including drug loading, release profile, size 
distribution and stabilities.25 Most commonly, chemotherapy drugs are encapsulated in NPs 
through hydrophobic interaction, which usually demonstrate unsatisfactory drug loading. For 
example, drug loading of doxorubicin (DOX) and camptothecin (CPT) in PEG-PLA micelle are 
typically below 5%.26-34 Thus, to achieve drug concentration that meet therapeutic window, 
significant amount of carrier molecules has to be introduced, which is not satisfactory from 
translation prospective. On the other hand, drug-polymer conjugate approach is able to load 
chemotherapy drugs in more efficient manner, but suffered from unsatisfactory drug release 
profile because of covalent linkage.35-38 Thus, it is of great need but challenging to design 
polymeric micelle systems with high drug loading while also bearing characteristics such as 




Scheme 3.1 Schematic illustration of the encapsulation of hydrophobic drugs in polymeric 
micelles.  
As mentioned previously, the interaction between drug and polymer dominates the formulation 
characteristics of drug incorporated micelles. Hydrophobic interaction, which is mostly utilized 
in previous systems, served as driving force for drug encapsulation and stabilization of drugs 
from precipitating out in physiological conditions. However, hydrophobic interaction between 
drug and polymer face competition of interaction between drug molecules with themselves and 
polymer packing. For example, drugs like DOX and CPT have conjugated systems which 
interact with each other through pi-pi stacking. The lack of specificity of interaction between 
drug and polymer vehicle usually yield low drug loading efficiency and heterogeneity of the 
formulation. As a result, it is highly demanded to develop chemistry that increase the interaction 
of drug and polymer while not generating significant problem with drug release profile. 
The interaction between Lewis acid and Lewis base is a unique molecular force between electron 
donor and electron receptor.39-41 Although Lewis base functional groups are widely present in 
biological environment, such as amines and thiol groups, Lewis acid is less seen in biological 
context. As previously demonstrated by our group, boronic acid on polymer side chains interact 
with chemotherapy drugs through electron donor-acceptor coordination. This specific 
interaction, unlike hydrophobic interaction, facilitated stable polymer micelle formation with 
high drug loading and desired release profile. Because of the reversible nature of the 
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coordination bond, the drug structure is preserved, which can be beneficial towards high drug 
bioavailability.42, 43 
As previously demonstrated in Chapter 2, OCA and its polymerization provide unique potential 
in synthesizing polyesters with abundant functional side groups. The resulting poly(α-
hydroxyalkanoic acid) with modification on pedant chains would also undergo backbone 
degradation to small molecules, providing its biodegradability. To demonstrate the advantage of 
this specific polymer chemistry, in this section, we developed a polyOCA based micelle system 
for high drug loading, quantitative encapsulation, controlled release and efficient drug delivery in 
application relevant environments. 
3.2 Synthesis and characterization of polymers 
In order to introduce side chain boronic acid groups, we developed the click chemistry based side 
chain modification. In detail, Alk-TyrOCA was synthesized according to previous report. The 
OCA was initiated from mPEG5k-OH under the catalysis of DMAP. Four different polymers with 
designed repeating unit of 5, 10, 15 and 20 were synthesized using this method. The polymers 
molecular weight and obtained DP were characterized using NMR method. From the ratio of 
integration of methine proton from PAHA block and the methylene peak from the PEG block, 
we were able to quantify the obtained repeating unit of these four polymers to be 4.2, 9.8, 14.9, 
and 21.2, respectively. The four polymers were post-modified with pinacol protected boronic 
ester with azido groups. The pinacol groups were cleaved under mildly acidic condition using 
sodium periodate as oxidizer. The resulting polymers, Pn-PBA (n = 5, 10, 15, 20), were 
characterized using NMR to ensure complete exposure of boronic acid groups. The side chain 
modification efficiency was quantified by NMR integration as well. At the same time, control 
polymers were also synthesized from the same mPEG-b-PAHA through copper catalyzed click 
reaction with Bn-Az, which shared the same structure with Pn-PBA except for the boronic acid 
group. The four control polymers were named Pn-Bn. 
3.3 Micelle formulation and characterization 
We first evaluated the micelle formulation of Pn-PBA with DOX. Upon mixing Pn-PBA solution 
with DOX in DMF, the solubility of DOX increased, indicating the interaction between polymer 
and drug molecules. The DMF solutions of Pn-PBA with DOX at polymer to drug ratio of 2:1 
were added dropwise into pure water with vigorous stirring. Visually clear red solutions were 
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obtained for all four entries. Micelle solution formulated from P5-PBA was not stable upon 
dialysis, resulting in DOX precipitating out from solution (Table 3.1). The other three micelle 
solutions were stable throughout the dialysis process. The size of formulated micelle was below 
100 nm for P10-PBA and P15-PBA, while micelle formulated from P20-PBA was larger than 
100 nm characterized by dynamic light scattering (DLS), presumably because of the imbalanced 
length of the hydrophobic block as compared to the PEG hydrophilic block. As comparison, 
DMF solutions of Pn-Bn and DOX with same polymer to drug ratio were also nanoprecipitated 
into pure water. Not surprisingly, DOX precipitate out from all four solutions instantly, 
consistent with literature reported scenarios, where less than 5% of DOX could be encapsulated 
in polyesters with only hydrophobic interactions. Brief stability test was conducted with micelle 
formulated from P10-PBA and P15-PBA (Figure 3.1). In phosphate buffer (PBS) at pH = 7.4, 
micelle formulated from P10-PBA slightly increased over time, presumably because of 
destabilizing because of DOX release. On the other hand, micelle formulated from P15-PBA 
didn’t change much over the 48 h incubation, demonstrating desired stability against ions. 
Table 3.1 Formulation results of Pn-PBA, Pn-Bn with DOX 
Micelle Polymer P/D ratioa Size (nm)b 
P5-PBA-DOX P5-PBA 2:1 >500 
P10-PBA-DOX P10-PBA 2:1 36.7 
P15-PBA-DOX P15-PBA 2:1 49.6 
P20-PBA-DOX P20-PBA 2:1 236.2 
P5-Bn-DOX P5-Bn 2:1 >1000 
P10-Bn-DOX P10-Bn 2:1 >1000 
P15-Bn-DOX P15-Bn 2:1 >1000 
P20-Bn-DOX P20-Bn 2:1 >1000 
aP/D ratio represent the weight ratio of polymer to doxorubicin drug in nanoprecipitation 




Figure 3.1 Stability of Pn-PBA-DOX micelles in PBS at 37 oC. 
Table 3.2 DLC and DLE of different micelles 
Entry Polymer P/D ratioa Size (nm)b DLC (%)c DLE (%)c 
P15-PBA-DOX-1 P15-PBA 1:1 35.6 ± 1.2 48.3 92 
P15-PBA-DOX-2 P15-PBA 1.5:1 29.9 ± 0.4 39.0 92 
P15-PBA-DOX-3 P15-PBA 2:1 31.9 ± 0.8 32.2 94 
P15-PBA-DOX-4 P15-PBA 5:1 43.4 ± 0.5 15.7 94 
aP/D ratio represent the weight ratio of polymer to doxorubicin drug in nanoprecipitation 
solution. bMeasured by dynamic light scattering. cCalculated from quantified amount of 
doxorubicin in lyophilized micelle samples using HPLC methods. 
Based on preliminary results, we picked P15-PBA as our best performing polymer and moved on 
to quantitatively characterize its formulation behavior with DOX. P15-PBA and DOX were 
mixed at P/D ratio of 1:1, 1.5:1, 2:1, and 5:1. The micelles formulated after nanoprecipitation 
were dialyzed against DI water. The size and distribution of micelles were measured in DLS. No 
large aggregates were observed for all entries. Homogenous micelle with small size (< 50 nm) 
and monomodal distribution was obtained. The sizes of PB-DOX were further confirmed by 
TEM images (Figure 3.2). As comparison, P15-Bn and DOX were formulated at same P/D ratio. 

















Even at 5:1 ratio, the control polymer was not able to prevent DOX from aggregation, which 
resulted large particles and broad distribution (> 500 nm). The drug loading content (DLC) of 
micelles prepared from P15-PBA was quantified by dissolving lyophilized micelle powders in 
acetonitrile with TFA added to destabilize the coordination interaction. The micelles showed 
drastically improved DLC with highest approaching 50 % along with sub-quantitative drug 
loading efficiency (DLE, >90%, Table 3.2).  
 
Figure 3.2 Representative TEM image of P15-PBA-DOX-3 
The distinctly different drug loading behavior of the two polymers most likely is the result of 
enhanced interaction between DOX and boronic acid. The side chain boronic acid was able to 
coordinate with amine group of DOX molecule, suppressing its aggregation tendency in water. 
To note, in micelle with P/D ratio of 1:1, the molar amount of boronic acid was less than the 
molar amount of DOX. However, this micelle was still stable throughout the dialysis purification 
step. The excess amount of DOX was presumably stabilized by the hydrophobic interaction 
between DOX molecules in the micelle core. When we perform HPLC analysis of the micelle 
solution diluted in organic solvent, the elution time of peak from PB-DOX was identical to free 
DOX, while the amount matched feed ratio. Thus, it is evidenced that DOX was encapsulated in 





Figure 3.3 Stability of P15-PBA-DOX-3 micelles in a) PBS pH = 7.4, b) PBS with 10 % FBS, 
and c) PBS with 100 μM of H2O2. 
The stability of P15-PBA-DOX was systematically studied. The micelle size didn’t change 
significantly upon incubation in PBS (Figure 3.3-a) or FBS containing PBS (Figure 3.3-b), 
indicating good stability in circulation mimicking environment. As arylboronic acid could be 
oxidized and cleaved by ROS (e.g., H2O2), we performed micelle stability test in PBS containing 
100 μM of H2O2 which is an intracellular relevant concentration. The micelle size increased after 
only 5 hours of incubation, and resulted in drug aggregation after 24 hours incubation (Figure 
3.3-c). The loss of boronic acid side chain because of reaction with peroxide caused loss of 
donor-accepted interaction between polymer and DOX, which also demonstrated the crucial role 
boronic acid played in stabilizing PB-DOX micelles. The reaction between P15-PBA with H2O2 
was further confirmed using a model NMR study. The new peaks were assigned to the phenol 
analog generated from oxidizing arylboronic acid (Figure 3.4). 
DOX release from PB-DOX micelle was also studied. The micelles were incubated in PBS 
buffer with 0.5 % of tween 80 to ensure solubility of release DOX. Acidic pH (pH = 5.5) 
accelerated drug release from PB-DOX micelle, presumably because of the protonation of DOX 
destroyed the coordination interaction between P-PBA and DOX (Figure 3.5-a). Interestingly, 
lysine and glucose seemed to have little impact on the release of DOX (Figure 3.5-b). This 
indicated that the interaction between DOX and P15-PBA was relatively stable at neutral pH, 
resistant to the competition binding from sugars and amino acids in cellular media. As for 
hydrogen peroxide, it facilitated DOX release at acidic condition but not at neutral condition, 
which is understandable considering the oxidation kinetics (Figure 3.5-c). At last, we also tested 
the DOX release from PB-DOX micelles with different DLC. Micelles with high DLC showed 
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similar release profile while DOX released faster from micelles with lower DLC, presumably 
because of the relatively weaker hydrophobic interaction in micelle core (Figure 3.5-d). 
We then tested the in vitro cytotoxicity of the polymer and DOX-loaded micelles in MDA-MB-
231 cells. P-PBAs were almost nontoxic to cells at concentration up to 100 μg/mL. In 
comparison, PB-DOX micelles demonstrated dose-dependent cytotoxicity to MDA-MB-231 
cells, achieving IC50 at similar range as compared to free DOX (Figure 3.6). This result clearly 
indicated that upon uptake by cancer cells, the loaded DOX was released and killed cancer cell in 
equal efficiency as compared to free drug. 
In conclusion, we report a PAHA based system to prepare polymeric micelles with high drug 
loading via incorporation of donor-accepter interactions between side chain boronic acid groups 
and amine bearing doxorubicin. The micelle afforded high drug loading and high drug loading 
efficiency, along with sub-50 nm size and good stability. Additionally, the encapsulated drug can 
be released in cancer related acidic condition and kill cancer cells efficiently. 
 
 




Figure 3.5 Doxorubicin release study of Pn-PBA-DOX micelles. a) Comparison of DOX release 
at different pH. b) Potential competition binding molecules’ effect on release. c) Hydrogen 




Figure 3.6 Cytotoxicity of DOX loaded micelles toward MDA-MB-231 cells after 48 h of 
incubation (n = 3). 
 
3.4 Materials and methods 
Materials: ALL chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise noted. DL-(Alkynl)TyrOCA was synthesized according to literature reported procedure. 
Anhydrous tetrahydrofuran (THF) was dried by an alumina column and stored in glove box. d8-
THF, isopropanol, and L-methyl lactate were dried by 4Å molecular sieve to remove trace 
amount of water. OCAs were recrystallized three times and stored at -30 oC in glove box.  
Instrumentation: NMR spectra were recorded on Varian U500 (500 MHz), VXR-500 (500 
MHz), Varian U600 (600 MHz) spectrometers. Infrared spectra were recorded on a Perkin Elmer 
100 serial FT-IR spectrometer. Quantified FT-IR spectra were obtained using IR liquid 
transmission cell (Specac Inc., Swedesboro, NJ, USA). Gel permeation chromatography (GPC) 
experiments were performed on a system equipped with an isocratic pump (Model 1260, Agilent 
Technology, Santa Clara, CA, USA), a DAWN HELEOS multiangle laser light scattering 
(MALLS) detector, and an Optilab rEX refractive index detector (Wyatt Technology, Santa 


























performed using serially connected size exclusion columns (100 Å, 103 Å, 104 Å, 105  Å, and 
106  Å Phenogel columns, 5 µm, 300 × 7.8 mm, Phenomenex, Torrance, CA, USA) at 60 °C 
using DMF containing 0.1 M LiBr as the mobile phase.  The molecular weights of polymers 
were determined from the dn/dc value assuming 100% mass recovery using ASTRA software 
(Version 6.1.1, Wyatt Technology). Analysis of DOX in the PBA/DOX mixture was performed 
on a Shimadzu HPLC system (LC-20AT) connected with PDA detector (SPD-M20A). Shimadzu 
C18 column (3 µm, 50 mm × 4.6 mm) was used for analysis. Gradient method was adopted 
using 0.1% TFA-H2O and acetonitrile as the mobile phase. HPLC analysis of free drug in the 
DOX-loaded P-PBA micelles was performed on Agilent 1220 LC system, with a mixture of 
acetonitrile and water (4:1, v/v)containing 0.1% TFA as the mobile phase. The column effluent 
was detected at 480nm with a UV/Visible detector. The column type was Agilent eclipse plus 
C18 (3.5μm, 4.6mm×100mm). The size and zeta potential of particles in the aqueous solution 
were measured by dynamic light scattering(DLS)conducted on a Malvern Zetasizer Nano ZS90 
with a He-Ne laser (633 nm) with 90° collecting optics. All the sizes were presented in terms of 
intensity diameter unless otherwise specified. 
Cell Culture: MDA-MB-231 triple-negative breast cancer cell, was purchased from American 
Type Culture Collection (Manassas, VA, USA). Cells were cultured in RPMI-1640 containing 
10% FBS, 100 units/ml Penicillin G and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA, 
USA) at 37 °C in 5% CO2 humidified air. 
Drug loading of Pn-Bn and Pn-PBA micelles: The drug-loaded micelles were prepared by the 
typical nanoprecipitation method. DOX·HCl was first neutralized by triethylamine (1.5molar 
equivalents to DOX) in DMF. Pn-PBA or Pn-Bn was dissolved in DMF and mixed with the 
DOX solution. The mixture was gently mixed, and then added dropwise into DI water under 
vigorous stirring. The mixture was stirred in the dark for another 30 min. DMF and other small 
molecules were removed by ultrafiltration (MWCO 3500 Da) against DI water for 5 times. The 
drug aggregate was removed by filtration through 0.45-μm membrane. The drug-loaded micelles 
solution were readily used for further study. To determine the DOX content in the micelles, they 
micelles were lyophilized, weighed and dissolved in acetonitrile and measured for the 
absorbance at 480 nm by the UV-Vis spectrometer. Drug loading content (DLC, wt%) and drug 
loading efficiency (DLE, wt%) were calculated according to the following formula: 
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DLC = (amount of loaded drug / amount of drug-loaded NPs) × 100% 
DLE = (amount ofloaded drug /amount of feeding drug) × 100% 
Aqueous solubility and colloidal stability of DOX-loaded Pn-PBA micelles: To explore the 
colloidal stability, PB-DOX micelles were diluted in PBS (pH 7.4) or PBS containing 10% FBS, 
and then the solutions were placed at 37 °C under gent shaking (100 rpm). At pre-determined 
time intervals (3, 6, 12, 24, and 48 h), an aliquot of the solution was withdrawn and measured by 
DLS.  
H2O2-triggered degradation of Pn-PBA and disassembly of micelles: P15-PBA (8mg) was 
dissolved in d6-DMSO (0.50 mL) with H2O2 (molar amount equal to the pendant phenylboronic 
acid) at room temperature. At pre-determined time intervals, 1H NMR measurement was 
performed to evaluate the degree of degradation of the polymer. 
The disassembly of drug-loaded P-PBA micelles was also investigated in the presence of 100 
µM of H2O2. PB-DOX micelles were dissolved in PBS (pH 7.4) containing 100 µM H2O2, and 
the suspension was placed at 37 °C. At pre-determined time intervals, particle size of the 
micelles was measured by DLS. 
In vitro drug release: The drug release from micelles was studied using PBS (pH 7.4) 
containing 0.5% tween 80, PBS (pH 7.4) containing 0.5% tween 80 and 100 μM H2O2, PBS (pH 
7.4) containing 0.5% tween 80 and 1.0 mg/mL lysine, PBS (pH 7.4) containing 0.5% tween 80 
and 1.0 mg/mL glucose,  or PBS (pH 5.5) containing 0.5% tween 80. Briefly, PB-DOX micelles 
(0.6 mL, containing 100μg DOX) were placed in a dialysis bag (MWCO 3500 Da), which was 
immersed in 15 mL of the release medium. The release study was performed at 37 °C under 
gently shaking (100 rpm). At pre-determined time intervals, 0.3 mL of the release medium was 
withdrawn and replaced with equal amount of fresh release medium. The DOX amount in the 
release medium was determined by HPLC quantification. 
In vitro anti-cancer efficacy: To evaluate the anti-cancer efficacy of DOX-loaded micelles, 
MDA-MB-231 cells were treated with DOX-loaded micelles in 96-well plates for 48 h at various 
DOX concentrations. After incubation, the cell viability was measured by the MTT assay. Cells 
that did not receive treatment with polymer served as the control, and results were denoted as 
percentage viability of control cells. 
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Scheme 3.2 Synthetic illustration of Pn-PBA and Pn-Bn 
 
Synthesis of PEG-p(Alk)TyrOCA. In a glove box, DMAP catalyst (20 mM) mPEG5k-OH (20 
mM), and OCA (100 mM) were separately dissolved in anhydrous THF to obtain stock solution. 
DMAP solution (100 µL) and mPEG5k-OH solution (100 µL) was added into a 7-mL glass vial 
equipped with a magnetic stir bar and diluted with THF (1.0 mL). The OCA solution (0.20 mL 
for [M]:[I] = 10) was added into catalyst solution under stirring. After reaction was complete, 
resulting polymers were precipitated in hexane and dried to give final product. 1H NMR (500 









Scheme. 3.3 Synthesis of 4-(2-azidoacetyloxymethyl)phenylboronic acid pinacol ester 
 
Synthesis of 4-(2-azidoacetyloxymethyl)phenylboronic acid pinacol ester. In a 50 mL flast, 4-
(Hydroxymethyl)phenylboronic acid pinacol ester (1.5 g, 6.4 mmol), N-hydroxysuccinimide 2-
azidoacetate (1.9 g, 9.6 mmol) and 4-dimethylaminopyridine (DMAP, 78 mg, 0.64 mmol) were 
dissolved in 20 mL of dichloromethane. The mixture was stirred for 16 hours at room 
temperature. After evaporating solvent in vacuum, the crude product was purified through silica 
gel chromatography (eluent: hexane: DCM: ethyl acetate = 4:4:1) to yield crystalline solid. 1H 
NMR (500 MHz, CDCl3): δ 7.81 (d, 2H), 7.36 (d, 2H), 5.24 (s, 2H), 3.91 (s, 2H), 1.35 (s, 12H); 
13C NMR (126 MHz, CDCl3): δ 168.13, 137.75, 135.12, 127.60, 83.94, 67.41, 50.36, 24.87; 
11B 
NMR (160 MHz, CDCl3): δ 30.91 
Synthesis of Pn-PBA. In a 7 mL vial, 4-(2-azidoacetyloxymethyl)phenylboronic acid pinacol 
ester (247 mg, 0.78 mmol) and mPEG-pAlkTyrOCA (210 mg, 0.39 mmol of alkynyl group) 
were dissolved in 4 mL DMF. Copper sulfate pentahydrate (20 mg, 0.078 mmol) was dissolved 
in 500 µL of DI water and added to the mixture. Sodium ascorbate (154 mg, 0.78 mmol) was 
dissolved in 2.0 mL of DI water and added lastly to the reaction mixture. The click reaction was 
performed at room temperature for 16 h. After reaction completed, EDTA disodium salt (30 mg) 
was added to the reaction mixture and stirred in open air for 30 min. Small molecules was 
removed by dialyzing against DI water (MWCO 3500). The resulting polymer solution (10 mL) 
was used directly for cleaving pinacol protecting group. Sodium periodate (250 mg, 1.17 mmol), 
ammonium acetate (150 mg, 1.95 mmol) and 10 mL of acetone was added to the reaction 
mixture. The solution was stirred overnight and small molecule impurities was removed by 
dialyzing against DI water (MWCO 3500). The final white power polymer was obtained by 
lyophilization. 1H NMR (500 MHz, d8-DMSO + 1 drop of conc. DCl): δ 8.16 (s, 1H), 7.68 (s, 
2H), 7.33 (s, 2H), 6.7-7.1 (b, 4H), 5.0-5.4 (b, 7H), 3.51 (s, PEG), 2.9-3.1 (b, 2H). 
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Synthesis of Pn-Bn. In a 7 mL vial, benzyl 2-azidoacetate (21.3 mg, 0.112 mmol) and mPEG-
pAlkTyrOCA (30 mg, 0.055 mmol of alkynyl group) were dissolved in 0.4 mL DMF. Copper 
sulfate pentahydrate (2.8 mg, 0.011 mmol) was dissolved in 50 µL of DI water and added to the 
mixture. Sodium ascorbate (22.1 mg, 0.11 mmol) was dissolved in 0.2 mL of DI water and added 
lastly to the reaction mixture. The click reaction was performed at room temperature for 16 h. 
After reaction completed, EDTA disodium salt (10 mg) was added to the reaction mixture and 
stirred in open air for 30 min. Small molecules was removed by dialyzing against DI water 
(MWCO 3500). The final white power polymer was obtained by lyophilization. 1H NMR (500 
MHz, CDCl3): δ 7.71 (s, 1H), 7.32 (b, 5H), 6.6-7.0 (b, 4H), 5.0-5.3 (b, 7H), 3.66 (s, PEG), 2.8-
3.0 (b, 2H). 
 






Figure 3.8 1H NMR spectrum of 4-(2-azidoacetyloxymethyl)phenylboronic acid pinacol ester in 
CDCl3 (x axis, δ ppm). 
 
Figure 3.9 13C NMR spectrum of 4-(2-azidoacetyloxymethyl)phenylboronic acid pinacol ester in 
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Gene therapy showed great promise for the treatment of genetic disease by delivering nucleic 
acid into target cells to either promote or suppress gene expression.1-5 Non-viral vectors for gene 
delivery has been actively explored for addressing problems associated with the usage of viral 
vectors, including their significant immunogenicity and potential mutagenesis or oncogenicity.6, 7 
Cationic polymers, capable of condensing anionic nucleic acids to facilitate their intracellular 
transport, are one of the most important classes of non-viral vectors. Polycations with higher 
molecular weight usually demonstrate stronger binding capacity towards nucleic acids, but also 
showed significant toxicity related to their high Mn and high charge density.8, 9  
Polypeptide is one of the firstly developed non-viral gene delivery system.10-15 With defined 
sequence, cell penetrating peptides (CPP) show high membrane activity and can facilitate 
attached cargos to transport through cell membrane.16-19 However, when used as gene delivery 
vector, CPP s are often too short to condense DNA and achieve efficient transfection.20, 21 
Polypeptide with sufficient length such as poly-L-lysine and poly-L-arginine, can condense DNA, 
but suffers from poor membrane activity because of their random-coil conformation in water.22, 
23 Recently our group developed synthetic polypeptide system which can maintain helix 
conformation with elongated distance between cationic group and backbone.24-27 These materials 
showed much higher transfection efficiency compared to CPPs and traditional polypeptides such 
as PLL and PLR. However these materials have toxicity related to high molecular weight and 
slow degradation profile due to slow hydrolysis of amide bond in water, which remains an issue 
when pushing towards future application. Thus we tried to develop a polypeptide-like polymeric 
system with faster degradation profile which can still maintain high transfection efficiency. 
Polyesters are a class of well-known biodegradable materials and have been commonly used in 
controlled release and drug delivery application.28-30 Ring opening polymerization of O-
carboxyanhydrides (OCAs) have recently been reported.31, 32 In the presence of 4-
dimethylaminopyridine (DMAP), OCAs can readily polymerize from primary alcohol and the 
resulting polymer have peptide-like side chains with controlled molecular weights and narrow 
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distribution. In this chapter, we report the design and synthesis of a series of side-chain aminated 
poly(α-hydroxy acid) (PAHPs) with different tertiary amine groups. By comparing their gene 
delivery capabilities in HeLa cell lines, we found out the best performing polymer, PAPHP-1, 
which were further comprehensively explored and studied in terms of its cell uptake level, 
intracellular kinetics, cytotoxicity change during degradation in aqueous solution. We found that 
PAPHP-1 showed comparable transfection efficiency compared to commercial available 
standard Lipofectamine™ 2000, and have significantly reduced cytotoxicity after degradation. 
This study provides insights into design strategy of biodegradable and efficient non-viral vectors 
for gene delivery. 
 
4.2 Synthesis and characterization of polymers 
 
Scheme 4.1 Schematic illustration of synthesis and post-modification of poly(3-(4-
allyloxylphenyl-2-hydroxylpropionate) (PAPHP-m) 
We first synthesized four PAHAs with different amino group side chains (Scheme 4.1). The 
PAHA were initiated from pyrenebutanol and DMAP with feeding monomer to initiator ratio of 
100. GPC analysis demonstrated high level of molecular weight control of OCA polymerization. 
The poly(allylTyrOCA) was post-modified through thiol-ene reaction to introduce tertiary amine 
group with different hydrophobicity. The resulting cationic polymers, PAPHP-m, were 
characterized by NMR and GPC methods. Post modification through thiol-ene reaction achieved 
>90 % modification efficiency, and the Mn increased as compared to poly(allylTyrOCA), which 
was attributed to the pedant cationic groups added to the polymer backbone and some level of 
photo-crosslinking of side chain ethylene units (Table 4.1). Polyplexes formation from PAPHP-
m and plasmid DNA was investigated using zetasizer. Figure 4.1 showed the particle size and 
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zeta potential of polyplexes from PAPHP-m and model plasmid DNA (pCMV-Luc). Above N/P 
ratio of 2.5, all 4 PAPHP-m formed sub-200 nm polyplexes with positive surface potential 
around 30 mV. This result demonstrated that cationic polyOCA successfully condensed DNA 
and form nano-sized complexes. The efficiency of incorporating DNA into polyplexes was then 
assayed by gel retardation assay. Polyplexes formulated at different N/P ratio ranging from 1 to 
30 were loaded onto polyacrylamide gel. After electrophoreses, free plasmid were imaged by 
ethidium bromide (Figure 4.2). From gel retardation result, PAPHP-m successfully condensed 
most of the plasmid DNA at N/P ratio higher than 5 at physiological pH, indicated by the 
disappearance of free plasmid band in gel. Of note, PAPHP-3 has lower binding affinity to 
plasmid DNA as compared to other three polymers, only able to fully condense DNA at N/P 
ratio higher than 10. This was attributed to the relatively low protonation of the amine groups. 
Table 4.1 Molecular weight and PDI of PAPHP-n 
 Mn (exp.) (kDa)
a Mn (cal.) (kDa)
b PDIa 
PAPHP-1 100mer 64.0 31.2 1.34 
PAPHP-2 100mer 68.9 34.0 1.78 
PAPHP-3 100mer 60.5 35.2 1.65 
PAPHP-4 100mer 72.1 33.8 1.57 
aDetermined by GPC analysis in DMF (0.1 M LiBr) using dn/dc from 100% recovery method. 




Figure 4.1 Size and zeta potential of nanocomplex formulated from PAPHP-n with pCMV-Luc 
at various N/P ratios. 
 
Figure 4.2 DNA condensation by PAPHP-m at various N/P ratios as evaluated by gel retardation 
assay (N represents naked DNA). 
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4.3 Polyester as gene delivery vector 
The polyplexes prepared from various PAPHP polymers and luciferase encoded plasmids were 
treated to HeLa cells for 4 hours in serum-free media followed by 48 hours of incubation for 
expression of encoded gene. The luciferase expression level was quantified using luciferin kit. 
Lipofectamine™2000 were used as positive control. From Figure 4.3, the in vitro transfection 
efficiency of polyplexes at various N/P ratios were compared to commercially available non-
viral vector. PAPHP-1 showed highest transfection efficiency, matching the expression level of 
Lipofectamine™2000. The transfection efficiency peaked at N/P ratio of 5 to 10 and decreased 
with more cationic polyester added. This was attributed to the toxicity brought by excess amount 
of cationic polymer as well as less likely of unpackaging/release of DNA intracellularly.  
 
Figure 4.3 In vitro transfection efficiencies of polyplexes at various N/P rations in HeLa cells in 
serum-free medium (n=3). 
I then studied the intracellular trafficking of the best performing PAPHP-1.33 The plasmid DNA 
were labeled with YOYO-1 for fluorescent imaging. As shown in Figure 4.4a, clear 
























































forming polyplexes, naked DNA uptake was negligible, demonstrating the crucial role PAPHP-1 
plays in the transfection process.  
 
Figure 4.4 Cell uptake level and intracellular kinetics of PAPHP-1/plasmid DNA (labeled with 
YOYO-1) complexes in HeLa cells. (a) Uptake of polyplexes in HeLa cells in 24-well plate at 
different concentration with fixed time or at different incubation time with fixed amount of DNA 
as measured by flow cytometry (n=3). Naked DNA served as the control. (b) Study of cell uptake 
mechanism of polyplexes using various endocytic inhibitors. Results were expressed as the 
percentage of uptake level of control cells in the absence of any inhibitors (n=3). (c) CLSM 
images of HeLa cells following incubation with polyplexes for 4 h. Scale bar = 10 μm 
The uptake mechanism of complexes was studied using endocytic inhibitors. We used PAPHP-1 
as model polymer. When HeLa cells was pretreated with different endocytosis inhibitor, various 
level of decrease occured for the uptake level of polyplexes. As chlorpromazine showed highest 
inhibition percentage of polyplexes uptake (Figure 4.4-b), the polyplexes were likely been uptake 
mostly through clathrin mediated endocytosis. Confocal image of HeLa cell (Figure 4.4-c) 
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showed that 4 hours after administer polyplexes, the YOYO-1 labeled plasmid DNA has been 
actively transported into the cytoplasm as majority of the green fluorescent does not co-localize 
with red fluorescence signal that indicate the endosomes. This result indicated that PAPHP-1 
successfully helped plasmid DNA to escape endosome and enter cytoplasm or even nucleus, 
supporting the high transfection efficiency observed in previous section. 
 
Figure 4.5 Schematic illustration of hydrolysis of PAPHP-1 and cytotoxicity assay of 
degradation products as compared to original PAPHP-1 in HeLa cells. (n = 3) 
We then evaluated if the degradability of polyester backbone would contribute to lowering the 
toxicity of polycations. We incubated PAPHP-1 and hydrolyzed products of PAPHP-1 with 
HeLa cells and assayed the cytotoxicity using MTT assay. As indicated in Figure 4.5, more than 
20 fold decrease of toxicity was achieved simply by cleaving the backbone polyester. This result 
was a clear indication of the benefit of lowering the toxicity of polycations by using PAHA 
backbones. 
In conclusion, we demonstrated in this chapter cationic side-chain modified PAHA system for 
efficient gene delivery to mammalian cells. A series of PAHAs with side chain tertiary amine 
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group grafted was synthesized through thiol-ene post polymerization modification. Focused 
screening of transfection of model gene in HeLa cells resulted in PAPHP-1, which outperform 
Lipofectamine™2000 in transfection efficiency. 
 
4.4 Materials and methods 
Materials and cell lines: Boc-L-tyrosine was purchased from Chem-Impex International (Des 
Plaines, IL, USA) and used as received. All other chemicals were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) and used as received unless otherwise indicated. Anhydrous 
tetrahydrofuran (THF), hexane and dimethylformamide (DMF) were dried by a column packed 
with 4 Å molecular sieves before use. Pierce BCA assay kits were purchased from ThermoFisher 
Scientific (Rockford, IL, USA). Plasmid DNA encoding luciferase (pCMV-Luc) was purchased 
from Elim Biopharmaceutics (Hayward, CA, USA). YOYO-1, LipofectamineTM 2000 
(LPF2000) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) were 
purchased from Invitrogen (Carlsbad, CA, USA). 
HeLa (human cervix adenocarcinoma) and HEK 293 (human embryonic kidney cells) were 
purchased from the American Type Culture Collection (Rockville, MD, USA) and were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Grand Island, NY, USA) containing 
10% fetal bovine serum and 1% penicillin-streptomycin. 
Instrumentation: 1H NMR spectra were recorded on a Varian U500 MHz or a VXR-500 MHz 
spectrometer. Gel permeation chromatography (GPC) experiments were conducted on a system 
equipped with an isocratic pump (Model 1100, Agilent Technology, Santa Clara, CA, USA), a 
DAWN HELEOS multi-angle laser light scattering (MALLS) detector (Wyatt Technology, Santa 
Barbara, CA, USA), and an Optilab rEX refractive index detector (Wyatt Technology, Santa 
Barbara, CA, USA). The detection wavelength of HELEOS was set at 658 nm. Separations were 
performed using serially connected size exclusion columns (100 Å, 500 Å, 103 Å and 104 Å 
Phenogel columns, 5 mm, 300 x 7.8 mm, Phenomenex, Torrance, CA, USA) at 60 oC using 
DMF containing 0.1 M LiBr as the mobile phase. The MALLS detector was calibrated using 
pure toluene and can be used for the determination of the absolute molecular weights (MWs). 
The MWs were determined based on the dn/dc value of each polymer sample calculated offline 
by using the internal calibration system processed by the ASTRA V software (version 5.1.7.3, 
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Wyatt Technology, Santa Barbara, CA, USA). HPLC was performed on a Shimadzu HPLC 
system (C18 column, 50 mm × 4.6 mm, 3 µm, Phenomenex). The UV wavelength for detecting 
pyrene and aromatic domain of polmer was set at 278 nm. 
Scheme 4.2. Synthetic route to (Allyl)TyrOCA (1) 
 
Synthesis of (S)-2-amino-3-(4-(prop-2-ene-1-yloxy)phenyl)propionic acid (4) 
Boc-L-tyrosine (10.0 g, 36 mmol, 1 equiv.) and Potassium carbonate (14.7 g, 108 mmol, 3 
equiv.) were suspended in anhydrous DMF (100 mL). Allyl bromide (12.9 g, 108 mmol, 3 
equiv.) was added dropwise at 0 ℃. The reaction mixture was stirred for 24 hours at room 
temperature. Water (300 mL) and Ethyl acetate (250 mL) were added. The aqueous phase was 
extracted with Ethyl acetate (3 x 150 mL). The combined organic phase was dried over 
anhydrous sodium sulfate and evaporated to give a colorless oil ((S)-2-(tert-
butoxycarbonyl)amino)-3-(4-(prop-2-ene-1-yloxy)phenyl)propionic acid allyl ester, 2), which 
was used in the next steo without further purification. The deprotection of 2 was performed with 
HCl/dioxane (4 M, 50 mL) at room temperature for 2 hours. After the solvent was removed 
under reduced pressure, a yellowish solid ((S)-2-Amino-3-(4-(prop-2-ene-1-
yloxy)phenyl)propionic acid allyl ester, 3) was obtained. The crude product was dissolved in 
H2O/THF (1:1, v/v, 100 mL) containing 4.2 g lithium hydroxide monohydrate. The reaction 
solution was stirred for 24 hours at room temperature. THF was evaporated under reduced 
pressure and the remaining aqueous solution was neutralized by adding concentrated HCl to 
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pH=6. The precipitate was filtered, washed with water (10 mL x 2), and dried in vacuum. A 
white powder was obtained (4, 6.30 g, 85% yield for 3 steps).  
Synthesis of (S)-2-hydroxyl-3-(4-(prop-2-ene-1-yloxy)phenyl)propionic acid (5) 
In a 250 mL round-bottom flask, 4 (2.21 g, 10.0 mmol, 1 equiv.) was dissolved in a mixture of 
acetic acid and water (1:1, v/v, 100 mL) and cooled to 0 ℃. Sodium nitrite (1.38 g, 20 mmol, 2 
equiv.) dissolved in water (20 mL) was added slowly to the M4 solution. The mixture was stirred 
for 5 hours at room temperature and 200 mL of water was added. The mixture was acidified to 
pH=1 using concentrated HCl and then extracted with ethyl acetate. The combined organic layers 
were washed with water (3 x 100 mL), dried over anhydrous sodium sulfate and evaporated to 
give a yellowish oil. Crude product was purified using chromatography on silica gel using 
chloroform: methanol: acetic acid = 90: 9: 1 as eluent. Final product was got as a white needle 
crystal. (1.2 g, 55% yield). 3-hydroxyl-3-(4-(prop-2-ene-1-yloxyl)phenyl)propionic acid was the 
main by-product.  
Synthesis of (S)-5-(4-(prop-2-ene-1-yloxy)benzyl)-1,3-dioxolane-2,4-dione ((allyl)TyrOCA, 
1) 
To an anhydrous THF solution (40 mL) containing 5 (1.2 g, 5.4 mmol), phosgene (10 mL, 10 
mmol, 15 wt. % in toluene) was added dropwise at 0 ℃. The mixture was stirred at room 
temperature for 24 hours. Solvent was removed under vacuum and the residue was purified by 
silica gel using DCM as eluent. The crude OCA was recrystallized in hexane/DCM in glove box. 
A colorless OCA monomer 1 was obtained in crystalline form (0.70 g, 54% yield). 
Polymerization of (allyl)TyrOCA.  
In a glove box, 1 (50 mg, 0.2 mmol) was dissolved in DCM (1 mL) followed by addition of 
pyrenebutanol (20 μL, 0.1 M in DCM) and DMAP (20 μL, 0.1 M in DCM). The conversion of 1 
was monitored by measuring the intensity of the anhydride peak of OCA at 1810 cm-1 by FTIR. 
After the polymerization was complete, polymer was precipitated with ether and dried under 
vacuum (37 mg, 90% yield). 1H NMR (500 MHz, CDCl3): δ 7.12 (d, 2H), 6.88 (d, 2H), 6.05 (m, 
1H), 5.40 (dd, 1H), 5.29 (dd, 1H), 5.27 (t, 1H), 4.52 (dt, 2H), 3.32 (dd, 1H), 3.20 (dd, 1H). 
General procedure of thiol-ene reaction of PAPHP with aminothiols. 
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In a 10 mL quartz vial, PAPHP (20 mg), hydrochloride salt of aminothiols (100 mg, 10 equiv. of 
alkene group), 2,2-Dimethoxy-2-phenylacetophenone (DMPA, 5 mg) was dissolved in 1 mL 
DMF/water (v/v, 9:1). The mixture was degassed by N2 for 10 min, then stirred at room 
temperature and irradiated under a 365-nm UV lamp (20 mW/cm2) for 60 min. The mixture was 
diluted using 5 mL of DI water and acidified to pH=5. The crude product was purified by 
ultrafiltration using Amicon Ultra-4 centrifugal filter unit (MWCO 3 kDa, Millipore, Billerica, 
MA, USA) and lyophilized (20 mg, 90% yield). The modification efficiency was determined to 
be 100% based on 1H NMR analysis. 
PAPHP-1: 1H NMR (500 MHz, d8-DMSO): δ 7.10 (2H), 6.87 (2H) 5.23 (1H), 4.10 (2H), 3.32 
(1H), 2.96 (9H), 2.54 (6H). 
PAPHP-2: 1H NMR (500 MHz, d8-DMSO): δ 7.01 (2H), 6.76 (2H), 5.19 (1H), 3.90 (2H), 2.62 
(12H), 1.89 (2H), 0.99 (6H) 
PAPHP-3: 1H NMR (500 MHz, d8-DMSO): δ 7.01 (2H), 6.78 (2H), 5.17 (1H), 3.94 (2H), 3.34 
(10H), 2.57 (2H), 1.87 (2H), 1.44 (6H) 
PAPHP-4: 1H NMR (500 MHz, d8-DMSO): δ 7.03 (2H), 6.79 (2H), 5.19 (1H), 3.91 (2H), 3.30 
(8H), 2.82 (2H), 2.62 (2H), 1.84 (6H) 
Characterization of degradation product of PAPHP-1 
PAPHP-1 (4 mg) was dissolved in NaOH solution (1 mL, 2 mol/L) and stirred at 40 ℃ for 3 
hours to let the ester bond fully hydrolysis. Then the mixture were diluted to 0.1 mg/mL for 
HPLC analysis. Initiator (Pyrenebutanol) and original polymer served as control.  
Preparation and characterization of PAPHP-x / DNA complexes. 
PAPHP-x and pCMVLuc plasmid DNA were separately dissolved in water at 1 mg/mL. DNA 
solution was diluted to 0.1 mg/mL and PAPHP-x solutions were diluted to 0.5 mg/mL using DI 
water. Complexes were allowed to form by addition of polymer solution to DNA solution at 
different N/P rations followed by vortex for 10 seconds and incubation at room temperature for 
10 min.  
Freshly prepared complexes were loaded on a 1% agarose gel at 200 ng DNA/well followed by 
electrophoresis at 115 V for 40 min. Naked plasmid DNA was used as control. DNA migration 
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in the agarose gel was visualized by Gel Doc imaging system (Biorad, Herclues, CA, USA) 
following staining with ethidium bromide (EB).  
Particle size and zeta potential of complexes at various N/P ratios were evaluated on Malvern 
Zetasizer Nano (Malvern Instruments Ltd., Malvern, Worcestershire, UK). 
In vitro transfection assay. 
HeLa cells were seeded on 96-well plated at 1x104 cells/well and cultured in serum-containing 
medium for 24 hours before reaching 80% confluence. The culture medium was changed to 
serum-free medium into which complexes were added at 100 ng DNA/well. After incubation for 
4 hours, the medium was replaced back to DMEM containing 10% FBS and cells were further 
incubated for 20 hours. Luciferase expression was assayed using a Bright-Glo luciferase assay 
kit while cellular protein level was determined using a BCA kit. Result were expressed as 
relative light unit (RLU) for each mg of cellular protein. 
Cell uptake study 
To allow visualization and quantification of cellular internalization of DNA, pCMV-Luc DNA (1 
mg/mL) was labeled with YOYO-1 (20 nM) at one dye molecule per 50 bp DNA and used to 
form complexes as described above, the N/P ratio of PAPHP-1/DNA complex was fixed at 10. 
Cells were seeded on 24-well plates at 5x104 cells/well and cultured until they reached 
confluence. The cell culture medium was changed to serum-free DMEM (0.5 mL/well) into 
which complexes were added at determined DNA amount (0.1, 0.2 and 0.5 μg YOYO-1 
DNA/well). After incubation at 37 ℃ for different time (0.5, 1, 2 and 4 hours), the medium was 
removed and cells were washed three times with PBS before assessment of YOYO-1-DNA 
uptake level by flow cytometry. 
To explore the mechanism involved during cellular internalization, cells were pre-incubated with 
endocytosis inhibitors including chlorpromazine (10 μg/mL), methyl-β-cyclodextrin (mβCD, 5 
mM), wortmannin (10 μg/mL) prior to addition of the YOYO-1 labeled DNA/polymer 
complexes and incubated for 2 hours. To block the energy dependent endocytosis, the cell uptake 
study was also performed at 4 ℃ during the 2-hour period. After incubation, cells were washed 
with PBS for 3 times and lysed with RIPA lysis buffer (500 μL/well) at room temperature for 20 
minutes. The YOYO-1-DNA content in the lysate was monitored by spectrofluorimetry (λex = 
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485 nm, λem = 530 nm) and the protein level was measured using the BCA kit. The result were 
expressed as percentage uptake of the control cells which were incubated with complexes at 37 
℃ for 2 hours in the absence of endocytic inhibitors. 
To explore the endosomal/lysosomal entrapment, HeLa cells were treated with YOYO-1-DNA 
containing complexes (1 μg/mL) for 4 hours at 37 ℃, stained with DAPI and Lysotracker®-Red 
according to the manufacturer’s protocol, and were visualized by confocal laser scanning 
microscopy. 
Cytotoxicity of PAPHP-1 and its degradation products 
Cells were seeded on 96-well plates at 1x104 cells/well and cultured in serum-containing 
medium for 24 hours. The medium was replaced with serum-free medium (100 μg/well), into 
which PAPHP-1 or degradation product were added at final concentration of 100 to 0.5 μg/mL. 
After incubation at 37 ℃ for 4 hours, the medium was changed to serum-containing DMEM and 
cells were further cultured for 24 hours before analyzed by MTT assay. Result were shown as 
percentage viability of control cells that did not receive any polymer treatment. 
 




Figure 4.7 1H NMR spectrum of PAPHP-1 100 mer in DMSO-d8. (500 MHz, x axis: δ ppm) 
 





Figure 4.9 1H NMR spectrum of PAPHP-3 100 mer in DMSO-d8. (500 MHz, x axis: δ ppm) 
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CHAPTER 5 CAGED METABOLIC PRECURSOR FOR DT-DIAPHORASE 
RESPONSIVE CELL LABELING* 
5.1 Introduction 
The research of metabolic glycoengineering has evolved rapidly over the last decades as it 
utilizes endogenous enzymes to process unnatural glycan substrates and introduces chemical 
functional groups onto proteoglycans and glycoproteins.1-3 Being combined with bioorthogonal 
Click chemistry,4, 5 these chemical anchors serve as powerful tools to understand and study 
glycans both on cell surfaces and in the cytoplasm, which result in improved understanding 
about proteomics,6-8 cell-cell interaction,9 and cell metastasis.10 Metabolic incorporation of 
unnatural sugar have opened up new directions in applied science, especially drug delivery and 
tumor imaging.11-15 One of the most studied unnatural sugar N-azidoacetylmannosamine 
(ManNAz) shares the same metabolic process with N-acetylmannosamine.6 The native hexose 
undergoes several steps of enzymatic processing and yields cytidine monophosphate-sialic acid 
(CMP-Neu5Ac) which is conjugated to cell surface glycans through post-translational 
modification in Golgi apparatus.3 This metabolic process is shared by most mammalian cell 
types, so the use of ManNAz to selective label specific types of cells has been proven to be 
difficult without interfering with their cellular metabolic machinery.3 
Currently, there are a few reports on controlling the metabolic labelling of ManNAz through 
different strategies. Cellular uptake levels determine the amount of potential unnatural sugars 
that can be metabolized in specific cells. Thus, researchers have developed delivery methods to 
enhance cellular uptake16, 17 or spatial availability of ManNAz towards cells of interest.13 Since 
ManNAz needs to go through metabolic processes inside cells, modification with caging groups 
on different positions of the unnatural hexose, namely anomeric14 or C-6 hydroxy groups,18, 19 
would provide extra control on its metabolic process. The metabolic precursor usually consists of 
three components: a metabolic labeling agent, a self-immolative linker and a trigger-cleavable 
cage group.20 These metabolic precursors have been demonstrated to have great potential in 
                                                 
* Part of this chapter is adapted from the publication: Wang, R.; Cai, K.; Wang, H.; Yin, C.; Cheng, J. “A caged 




cancer imaging19 and targeted delivery of drugs.14 However, in some cases, the self-immolative 
linker has compromised stability in physiological condition, which results in cleavage of the 
caged group even when their respective trigger was absent.18, 19 For example, it is reported that a 
caged precursor with peptide conjugated to Ac3ManNAz through carbonate bond on C-6 position 
showed nonenzymatic carbonate hydrolysis in the absence of trigger enzyme in degradation 
studies.18 Clearly, it is challenging to achieve trigger specific metabolic labeling with these 
existing linkers which can be cleaved nonspecifically in cellular environment. Our group 
previously developed a selective labeling technique which demonstrated that using ether linkages 
on the anomeric position of ManNAz successfully controlled the labeling process of ManNAz,14 
achieving selective metabolic labeling of cancer cells based on their different enzyme activity. 
However, the anomeric ether bond formation requires strong acidic condition, which hinders 
incorporation of acid labile caging groups such as Boc-protected oligopeptides. Therefore, it is 
important to design metabolic precursors with controlled decaging processes and feasibility to 
incorporate wide range of trigger responsive functionalities.  
 
Scheme 5.1 Scheme of three components of caged metabolite HQ-NN-AAM 
In this section, we report a new metabolic precursor (Scheme 5.1), HQ-NN-AAM, which 
contains a DT-diaphorase (DTD) responsive trimethyl quinone moiety (HQ)21, 22 and a self-
immolative dimethylethylenediamine (NN) linker attached to the anomeric position of ManNAz 
through N-methyl carbamate linkage.23, 24 The linkage was selected from our study of unspecific 
cleavage of various common linkers in typical cellular environments. The self-immolative linker 
also enables mild synthetic condition and avoids harsh acidic glycosylation reactions to couple 
trigger groups onto the anomeric position. HQ-NN-AAM was utilized to label multiple cell lines 
and incorporation of azido groups was achieved on cell surfaces. The labelling activity was 
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suppressed when DTD activity was inhibited, demonstrating the trigger-specific metabolic 
activity of HQ-NN-AAM. 
5.2 Self-immolative linker optimization 
 
Figure 5.1 Metabolic labeling of N-azidoacetylmannosamine is blocked by modification of N-
methyl carbamate linker on 1-hydroxyl group. a) Schematic illustration of controlled metabolic 
labeling by caging strategy. The dormant sugar activation depended solely on cellular trigger 
signal. b) Chemical structures of four control metabolic precursors with different linkers. c) 
Metabolic labeling of control metabolic precursors (50 μM) in multiple cell lines. d) 




To achieve controlled labeling with trigger responsiveness, two main requirements of the caging 
groups have to be met. First, the caged precursor should be efficiently de-caged under the 
designated trigger condition. Second, the cage group must resist non-specific degradation in a 
complex cellular environment when the trigger is absent (Figure 5.1-a). We synthesized four 
model compounds (Figure 5.1-b) to study suitable types of bond linkage on anomeric position of 
ManNAz that can resist cleavage from the complex subcellular environment. The anomeric 
hydroxyl position of ManNAz were caged with acetyl (Ac-AAM, ester linkage), ethoxycarbonyl 
(Et-O-AAM, carbonate linkage), N-butylcarbamate (Bu-N-AAM, carbamate linkage), and N-
methyl-N-((Boc-methylamido)ethyl)carbamate (Boc-NN-AAM, N-methyl carbamate linkage), 
respectively. We incubated these four caged sugars with a panel of six different cell lines at 
concentration of 50 µM for three days. The cells lines include Bxpc-3 (pancreatic cancer cells), 
MIA PaCa-2 (pancreatic cancer cells), A549 (lung cancer cells), MDA-MB-231 (breast cancer 
cells), HEK293 (embryonic kidney cell), and IMR90 (fibroblast cells). The azide labeling in all 
cells were analyzed by flow cytometry using DBCO-Cy5 as a probe. The cell surface azido 
glycan density was quantified through average Cy5 fluorescence intensity per cell. The labeling 
results (Figure 5.1-c) showed that the ester linkage (Ac-AAM) and the carbonate linkage (Et-O-
AAM) could not block the metabolic process, resulting in high metabolic labeling level in all six 
cell lines presumably due to the non-specifically hydrolysis of the ester and the carbonate bonds 
by intracellular esterses.2, 25 Carbamate linkage (Bu-N-AAM), on the other hand, showed partial 
block of the labeling, with reduced Cy5 fluorescence as compared to Ac-AAM and Et-O-AAM 
at the same sugar concentration. The N-methyl carbamate linkage (Boc-NN-AAM) showed 
negligible labeling in all six cell lines, indicating the promise of the linker for blocking the 
metabolic process of ManNAz. As shown by typical flow cytometry trace (Figure 5.1-d), the 
cells treated with Boc-NN-AAM showed similar fluorescence as compared to cells without any 
treatment, indicating the signal was predominantly contributed by passive uptake of DBCO-Cy5. 
On the other hand, cells treated with Ac-AAM or Et-O-AAM displayed higher fluorescence 
signal distribution, indicating predominant role of cell surface azido group attaching DBCO-Cy5 
through the Click reaction. 
5.3 DT-diaphorase triggered activation of metabolic precursor 
DTD has been reported to be overexpressed in multiple cancer cell lines and its high activity has 
been associated with hypoxia and cancer cell aggressiveness.26 Incorporating previous selected 
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best performing N-methyl carbamate linker, we designed a DTD responsive metabolic precursor, 
HQ-NN-AAM (Scheme 5.2). The conjugate consists of three major components, the HQ moiety 
which can be specifically reduced by DTD,21 NN linker with N-methyl carbamate linkage which 
can self-cyclize when the end amine is exposed,23 and the metabolic active precursor of 
triacetylated ManNAz (Figure 5.2-a). The synthetic route (Scheme 5.2) started with HQ-COOH 
which was prepared according to literature by N-bromosuccinimide (NBS) oxidizing the lactone 
precursor.21 HQ-COOH was coupled with mono-Boc protected N,N’-dimethylethylenediamine 
with N,N’-dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS) and 4-
dimethylaminopyridine (DMAP). The Boc protecting group was then removed in TFA/DCM. 
Ac3ManNAz-OH was synthesized according to literature report.
14 It was then activated using 4-
nitrophenol chloroformate to NB-O-AAM and coupled with HQ-NN under mild basic 
conditions.  
 
Scheme 5.2 Synthesis of HQ-NN-AAM  
After obtaining the caged sugar, we examined the trigger-responsive decaging process in 
physiological conditions of HQ-NN-AAM by HPLC. The designed decaging mechanism is 
shown in Figure 5.2-a. After the reduction to hydroquinone by DTD from the trimethylquinone 
structure, the cage group undergoes cyclization into lactone and exposed the amine group of the 
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NN linker, which also cyclizes into a five membered cyclic urea and expose the anomeric 
hydroxy group on ManNAz, finishing the decaging cascade process. 
 
Figure 5.2 DTD-responsive release of Ac3ManNAz-OH from HQ-NN-AAM. a) Schematic 
illustration of cascade degradation of HQ-NN-AAM under DTD trigger. b) HPLC trace of HQ-
NN-AAM (1), compound 3 (15 min), compound 4 (15 min) and Ac3ManNAz-OH (AAM-OH, 
210 min). c) Accumulative release of Ac3ManNAz-OH from HQ-NN-AAM with (red) or 
without (black) DTD. The slightly lower release of AAM was due to further hydrolysis of AAM-
OH. 
We characterized this degradation process in mimicked physiological condition (37 oC, pH = 
7.4). HQ-NN-AAM was first reduced in the presence of DTD and NADPH,27 resulting in 
hydroquinone 2. The hydroquinone structure cyclized into compounds 3 and 4 in less than 15 
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min. The products were characterized by LC-MS and HPLC (Figure 5.2-b). Compound 4 then 
undergoes cyclization and yielded the active metabolic reagent Ac3ManNAz-OH (AAM-OH) 
(Figure 5.2-b). The accumulative release of AAM into the reaction mixture reached plateau of 60 
% at around 2 h and slightly decreased afterwards, presumably because of the further hydrolysis 
of the pendant acetyl groups with the increased hydrophilicity. In comparison, NADPH was not 
able to trigger the decaging process of HQ-NN-AAM in the absence of DTD and there was only 
negligible degradation from hydrolysis of the pendant acetyl groups (Figure 5.2-c, black curve). 
These results demonstrated that HQ-NN-AAM was able to respond specifically to enzymatic 
degradation cues and release active metabolite efficiently within a few hours.  
5.4 Controlled cell labeling 
We examined the metabolic labeling of HQ-NN-AAM in cell lines with reported high DTD 
activity. We used MDA-MB-23126 and Bxpc-328 as model cell lines. HQ-NN-AAM showed 
efficient labeling in cells and the cell surface azide incorporation was confirmed by flow 
cytometry analysis (Figure 5.3-a). Boc-NN-AAM, which shares the same NN linker with inert 
Boc end group, showed minimal azide labeling while HQ-NN-AAM was able to efficiently label 
cells evidenced by the strong DBCO-Cy5 fluorescence (Figure 5.3-b). The metabolic labeling of 
azido sugar was also confirmed by laser scanning confocal microscopy (Figure 5.3-d). The Cy5 
fluorescent intensity and distribution of cells incubated with same concentration of Boc-NN-
AAM and HQ-NN-AAM showed distinct differences. The continuous red fluorescence on cell 
surface (co-localization with membrane stain, Figure 5.3-d) resulted from HQ-NN-AAM 
incubation indicated successful metabolic incorporation of azido sugar because of the decaging 
of HQ moiety in cells. On the other hand, cells treated with Boc-NN-AAM only showed weak 
punctuated red fluorescence signal inside cells, which was attributed to background cellular 
uptake of DBCO-Cy5. The metabolic labeling of HQ-NN-AAM was further validated using 
western blot (Figure 5.4). Cell surface azido concentration showed a positive correlation to HQ-
NN-AAM concentration ranging from 100 nM to 50 μM (Figure 5.5). We also performed 
labeling kinetic studies in MDA-MB-231 cells (Figure 5.6). HQ-NN-AAM showed similar 
labeling kinetics as compared to literature reported Ac4ManNAz kinetics,
14 reaching an azido 
concentration plateau at around 48 hours of incubation. This result indicated that the triggered 
releasing process of HQ-NN-AAM did not delay the metabolic process of ManNAz to cell 
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surface glycan, which was presumably due to the relatively fast release of AAM-OH from HQ-
NN-AAM in physiological condition.  
 
Figure 5.3 HQ-NN-AAM metabolic labelled cells. a) Flow cytometry histogram of metabolic 
labeling of HQ-NN-AAM (50 μM) and Boc-NN-AAM (50 μM) in MDA-MB-231 cells. b) 
Quantification of azido labeling in MDA-MB-231 cells and Bxpc-3 cells c) Flow cytometry 
histogram of metabolic labeling of HQ-NN-AAM (50 μM) with co-incubation of DTD inhibitor 
in MDA-MB-231 cells. d) Confocal image of HQ-NN-AAM and Boc-NN-AAM treated MDA-
MB-231 cells. Azido groups were labeled with DBCO-Cy5 (red) for visualization. Nucleus were 
stained with Hoechst dye (blue). Scale bar = 20 μm 
We next demonstrated the specificity of HQ-NN-AAM in response to endogenous DTD using 
inhibition assay. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) was used as an inhibitor of 
enzymatic activity of DTD.27 The surface azide concentration of MDA-MB-231 cells from 
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incubation with HQ-NN-AAM reduced after the pre-treatment with DMXAA (Figure 5.3-c), 
while the labeling of Ac4ManNAz was not interfered by the inhibitor (Figure 5.7). Western blot 
also confirmed the reduction of total azido sugar glycosylation level in cells with DMXAA 
treatment (Figure 5.8). The residue metabolic labeling at high concentration of inhibitor was 
presumably attributed to the non-specific reduction of HQ moiety by other reductase in cellular 
environments.  
 
Figure 5.4 Western blotting of azido labeled glycoproteins in MDA-MB-231 cell treated with 50 
μM of HQ-NN-AAM (Band 1), 50 μM of Boc-NN-AAM (Band 2) and no treatment (Band 3).  
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Figure 5.6 Labeling kinetics of different concentrations of HQ-NN-AAM in MDA-MB-231 cells 
analyzed by flow cytometry method 
  
Figure 5.7 Flow cytometry histogram and dot plot of cell surface azido concentration of MDA-
MB-231 cell treated with AAM and different concentration of DMXAA, DMXAA showed no 
effect on AAM labeling. 
















































Figure 5.8 Western blotting of azido labeled glycoproteins in MDA-MB-231 cell treated with 
HQ-NN-AAM and different concentration of DMXAA (DT-diaphorase inhibitor). 
 
5.5 Materials and methods 
Materials. DBCO–Cy5 were purchased from KeraFAST, Inc (Boston, MA, USA). EZ-Link 
phosphine–PEG3–biotin, streptavidin–horseradish peroxidase (HRP), and Pierce ECL western 
blotting substrate were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
Anhydrous dichloromethane (DCM), hexane, tetrahydrofuran (THF) and dimethylformamide 
(DMF) were purified by passing them through alumina columns. Phosphate-buffered saline 
(PBS), RPMI-1640 Medium and Dulbecco's Modified Eagle's Medium (DMEM) were obtained 
from Invitrogen (Carlsbad, CA, USA). F-12K medium and Eagle’s minimum essential medium 
(EMEM) were purchased from American Type Culture Collection (Manassas, VA, USA). Fetal 
Bovine Serum (FBS) was obtained from Lonza Walkersville Inc (Walkersville, MD, USA). BD 
Falcon culture plates were purchased from Fisher Scientific (Hampton, NH, USA). ProLong 
Gold antifade reagent was purchased from Life Technologies (Carlsbad, CA, USA). All other 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Instrumentation: NMR spectra were recorded on Varian U500 (500 MHz), VXR-500 (500 
MHz), or Bruker CB500 (500 MHz) spectrometers. HPLC analyses were performed on a 
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Shimadzu CBM-20A system (Shimadzu, Kyoto, Japan) equipped with a SPD20A PDA detector 
(190–800 nm), an RF10Axl fluorescence detector, and an analytical C18 column (Shimadzu, 3 
μm, 50*4.6 mm, Kyoto, Japan). Lyophilization was conducted in a Labconco FreeZone 
lyophilizer (Kansas City, MO, USA). Confocal laser scanning microscopy (CLSM) images were 
taken on a Zeiss LSM 700 Confocal Microscope (Carl Zeiss, Thornwood, NY, USA). Flow 
cytometry analyses of cells were conducted with a BD FACS Canto 6-color flow cytometry 
analyzer (BD, Franklin Lakes, NJ, USA). Western blotting membrane was imaged in 
ImageQuant LAS 4000 gel imaging system (GE, Pittsburgh, PA, USA). 
Cell culture. Bxpc-3 pancreatic cancer cell, MIA PaCa-2 pancreatic cancer cell, A549 lung 
cancer cell, MDA-MB-231 triple-negative breast cancer cell, HEK293 embryonic kidney cells, 
and IMR-90 human fibroblast cell lines were purchased from American Type Culture Collection 
(Manassas, VA, USA). Cells were cultured in RPMI-1640 containing 10% FBS, 100 units/ml 
Penicillin G and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) at 37 °C in 5% CO2 
humidified air unless otherwise noted. MIA Paca-2 cells were cultured in DMEM containing 
10% FBS. A549 cells were cultured in F-12K medium containing 10% FBS. HEK293 and IMR-
90 cells were cultured in EMEM containing 10% FBS. HBEC-5i were cultured in EMEM with 
10% FBS and 40 μg/ml endothelial growth supplement (ECGS). MCF-10A cells were cultured 
in MEGM BulletKit. 
General method for flow cytometry quantification of surface azido sugar 
Cells were seeded in 6-well plate one day before azido sugar treatment for fully attachment. 2 
mL of full growth media were replenished for each well before adding azido sugar. Azido sugars 
were added in stock solution of DMSO (100 mM) into cell culture wells to reach final designed 
concentration. The cells were cultured at 37 °C in 5% CO2 humidified air for designed time 
length. Then the culture media were removed and cells were washed with PBS for three times to 
remove residua free azido sugar. Fresh culture media with 50 M DBCO-sulfo-Cy5 were treated 
to cells for 45 min. Free dye were washed away with PBS for three times. The cells labeled with 
Cy5 were detached by trypsin and then fixed in 4% polyformaldehyde for flow cytometry 
analysis. 
HPLC quantification of enzymatic degradation of HQ-NN-AAM 
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NADPH stock solution (10mM in PBS, 100 L), human DT-diaphorase stock solution (200 
ug/mL in PBS, 20 μL) and HQ-NN-AAM stock solution (10 mg/mL in DMSO, 40 μL) were 
mixed and diluted in 840 μL of PBS. The mixture was incubated at 37 °C. At each assigned time 
data point, 20 μL of reaction mixture were quenched with 80 μL of cold HPLC water containing 
0.1% TFA (n = 3). The HPLC trace were collected at 204 nm (for quantification of non-aromatic 
molecule) and 262 nm (for quantification of molecule with aromatic domain). HPLC elution 
gradient were set from 20 % Acetonitrile to 80 % in 0.1 % TFA water. Each starting material, 
intermediate and final compound were quantified to standard curve generated from pure 
compounds. 
General method for Western blotting analysis of total azido glycoprotein 
Cells lysates were obtained by adding ice cold RIPA buffer to cells with azido sugar treatment. 
The lysate was incubated at 4 °C for 1 h and sonicated for 5 min for fully decomposition of cells. 
The lysate debris were removed by centrifuge. Protein concentration of cell lysate were 
quantified using BCA assay. Cell lysate were added with iodoacetamide stock solution (1.0 M in 
DMSO) to a final concentration of 15 mM and incubated at 37 °C for 30 min for fully blocking 
of thiol groups. DBCO-(PEG)4-biotin were added to the mixture to a final concentration of 50 
μM and incubated 37 °C for 2 hours. The protein mixture labeled with biotin were mixed with 
sample buffer subjected to electrophoresis. After standard membrane transfer, protein bands with 
biotin modification were detected by streptavidin-HRP and ECL western Blotting Substrate. 
General procedures for confocal imaging of azido sugar labeled cells. 
Cells were seeded onto coverslips in a 6-well plate at a density of 4 × 104 cells per well and 
allowed to attach for 12 h. Azido sugar (50 μM) was added and the cells were incubated at 37 °C 
for 72 h. After washing with PBS, cells were incubated with DBCO–Cy5 (50 μM) for 1 h 
followed by staining of cell nuclei and membrane with Hoechst 33342 (10 μM) and CellMask 
orange plasma membrane stain (1 μg/ml) for 10 min, respectively, and fixed with 4% 
paraformaldehyde (PFA) solution. The coverslips were mounted onto microscope slides and 
imaged under a confocal laser scanning microscope. 
Inhibition assay of azido sugar cell labeling.27 
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Cells were seeded in 6-well plate one day before azido sugar treatment for fully attachment. 
DMXAA stock solution (200 mM in DMSO) were added to freshly replenished cell culture 
media to final concentration designed (e.g. 100 μM). The cells were cultured for 2 h for 
inhibition of DTD activity before azido sugar stock solution were added. The cells were further 
cultured for 12 h and subjected to either flow cytometry analysis or Western blotting analysis of 
azido glycoprotein. 
Synthetic procedures 
Ac4ManNAz (Ac-E-AAM) and Ac3ManNAzOH (AAM) were synthesized according to literature 
report.14 
Scheme 5.3 Synthetic route of Et-O-AAM (1) and Bu-N-AAM (2) 
 
Synthesis of Et-O-AAM (1). Ac3ManNAzOH (78 mg, 0.2 mmol) were dissolved in 500 μL of 
anhydrous THF. Ethyl chloroformate (42 mg, 0.4 mmol) and pyridine (80 μL, 1.0 mmol) were 
added to the reaction mixture. The mixture were stirred at room temperature until starting 
material disappeared on TLC plate. The reaction were quenched by adding methanol and the 
solvent were removed in vacuum. The crude product was purified by silica gel column 
chromatography using ethyl acetate/hexane (1/1, v/v) to yield a colorless oil (65% yield, > 90% α 
isomer). 1H NMR (500 MHz, CDCl3): δ 6.55 (d, 1H, J = 9.2 Hz), 5.94 (d, 1H, J = 1.9 Hz), 5.37 
(dd, 1H, J = 10.2, 4.3 Hz), 5.23 (t, 1H, J = 10.1 Hz), 4.69 (ddd, 1H, J = 9.2, 4.3, 2.0 Hz), 4.26 
(m, 3H), 4.10 (m, 4H), 2.11 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H), 1.35 (t, 3H, J = 7.1 Hz). 13C NMR 
(125 MHz, CDCl3): δ 170.44, 169.85, 169.55, 166.65, 152.53, 94.41, 68.62, 65.15, 64.97, 61.65, 
52.44, 49.25, 41.01, 20.72, 20.62, 20.58, 14.11. HRMS-ESI (m/z): [M+Na]+ calculated for 
C17H24N4O11Na, 483.1339; observed, 483.1332. 
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Synthesis of Bu-N-AAM (2). Ac3ManNAzOH (78 mg, 0.2 mmol) were dissolved in 500 μL of 
anhydrous THF. n-butyl isocyanate (30 mg, 0.3 mmol) and dibutyltin dilaurate (5 μL) were 
added to the reaction mixture. The mixture were stirred at 50 oC until starting material 
disappeared on TLC plate. The solvent were removed in vacuum. The crude product was purified 
by silica gel column chromatography using ethyl acetate/hexane (1/1, v/v) to yield a colorless oil 
(72 % yield, mixture of α and β isomer, α:β = 1:4). 1H NMR (500 MHz, CDCl3), β isomer: δ 6.63 
(d, 1H, J = 9.0 Hz), 5.87 (d, 1H, J = 1.6 Hz), 5.16 (t, 1H, J = 9.9 Hz), 5.06 (dd, 1H, J = 9.9, 3.9 
Hz), 4.84 (t, 1H, J = 5.9 Hz), 4.72 (ddd, 1H, J = 9.0, 3.8, 1.6 Hz), 4.01-4.28 (m, 4H), 3.81 (ddd, 
1H, J = 9.8, 4.3, 2.4 Hz), 3.19 (m, 2H), 2.11 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H), 1.49 (m, 2H), 
1.34 (m, 2H), 0.92 (t, 3H); α isomer: δ 6.55 (d, 1H, J = 9.3 Hz), 5.97 (d, 1H, J = 1.9 Hz), 5.32 
(dd, 1H, J = 10.0, 4.2 Hz), 5.21 (t, 1H, J = 10.1 Hz), 4.91 (t, 1H, J = 5.9 Hz), 4.61 (ddd, 1H, J = 
9.4, 4.2, 2.0 Hz), 4.01-4.28 (m, 5H), 3.19 (m, 2H), 2.11 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H), 1.49 
(m, 2H), 1.34 (m, 2H), 0.92 (t, 3H),; 13C NMR (125 MHz, CDCl3), β isomer: δ 170.51, 170.11, 
169.57, 167.16, 153.08, 91.01, 73.08, 71.67, 64.98, 61.70, 52.67, 50.09, 41.03, 31.67, 20.72, 
20.68, 20.65, 19.84, 13.65; α isomer: δ 170.52, 170.24, 169.49, 166.59, 152.93, 91.93, 69.85, 
69.07, 65.23, 61.81, 52.46, 49.46, 40.95, 31.72, 20.79, 20.60, 20.04, 19.86, 13.68; HRMS-ESI 
(m/z): [M+Na]+ calculated for C19H29N5O10Na, 510.1812; observed, 510.1826. 
Scheme 5.4 Synthetic route of Boc-NN-AAM (5) 
 
 
Synthesis of tert-butyl methyl(2-(methylamino)ethyl)carbamate (Boc-NN, 3). N,N’-
dimethylethylenediamine (4.4 g, 50 mmol) were dissolved in 200 mL of DCM and cooled to 0 
°C. Di-tert-butyl dicarbonate (2.7 g, 12.5 mmol) were dissolved in 40 mL of DCM and added to 
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the diamine solution dropwise over 1 h. The mixture was slowly warmed up to room temperature 
and stirred for 16 h. After removing solvent in vacuum, the crude product was purified by silica 
gel column chromatography using ethyl acetate/ methanol/ trimethylamine (87/10/3, v/v) to yield 
colorless oil (80 %). 1H NMR (500 MHz, CDCl3): δ 3.32 (t, 2H), 2.97 (s, 3H), 2.72 (t, 2H), 2.44 
(s, 3H), 1.45 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 155.94, 79.44, 49.73, 48.43, 36.32, 34.71, 
28.45; HRMS-ESI (m/z): [M+H]+ calculated for C9H21N2O2, 189.1603; observed, 189.1606. 
Synthesis of NB-O-AAM (4). Ac3ManNAzOH (78 mg, 0.2 mmol) were dissolved in 3 mL of 
anhydrous DCM. 4-Nitrobenzyl chloroformate (48 mg, 0.24 mmol) and triethylamine (50 μL, 
0.4 mmol) were added to the reaction mixture. The mixture was stirred at room temperature until 
starting material disappeared on TLC plate. The reaction was quenched by adding 2 mL of 1 M 
dilute HCl in water. The product was extracted with DCM (10 mL x 3) and 4-nitrophenol was 
washed with saturated NaHCO3 (50 mL x 4). The organic phase were dried and evaporated under 
vacuum to give colorless product (85 %, mixture of α and β isomer, α:β = 2:1). 1H NMR (500 
MHz, CDCl3) β isomer: δ 8.32 (d, 2H, J = 9.2 Hz), 7.45 (d, 2H, J = 9.2 Hz), 6.58 (d, 1H, J = 9.1 
Hz), 6.07 (d, 1H, J = 1.9 Hz), 5.43 (dd, 1H, J = 10.1, 4.4 Hz), 5.29 (t, 1H, J = 10.1 Hz), 4.80 
(ddd, 1H, J = 9.1, 4.4, 2.0 Hz), 4.07-4.34 (m, 5H), 2.13 (s, 3H), 2.09 (s, 3H), 2.04 (s, 3H); α 
isomer: δ 8.34 (d, 2H, J = 9.3 Hz), 7.50 (d, 2H, J = 9.3 Hz), 5.93 (d, 1H, J = 6.7 Hz), 5.45 (dd, 
1H, J = 10.1, 4.4 Hz), 5.20 (dd, 1H, J = 6.6, 5.6 Hz), 4.92 (m, 1H), 4.47 (d, 1H, J = 2.4 Hz), 
4.07-4.34 (m, 5H), 2.12 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
170.38, 169.89, 169.48, 166.79, 154.86, 150.17, 145.78, 125.48, 121.64, 95.72, 61.56, 52.43, 
49.16, 20.71, 20.62, 20.59; HRMS-ESI (m/z): [M+Na]+ calculated for C21H23N5O13Na, 
576.1190; observed, 576.1180. 
Synthesis of Boc-NN-AAM (5). NB-O-AAM (4, 55 mg, 0.1 mmol), Boc-NN (3, 22 mg, 0.12 
mmol), N,N-diisopropylethylamine (DIPEA, 25 μL, 0.15 mmol) and 4-dimethylaminopyridine 
(DMAP, 1 mg, 0.01 mmol) were dissolved in 0.5 mL anhydrous DCM. The solution mixture was 
stirred at room temperature for 16 h. The solution was then diluted with 10 mL DCM and 
washed with 1 M HCl (50 mL x 2) and saturated NaHCO3 (50 mL x 3). The organic phase was 
dried using anhydrous Na2SO4 and concentrate in vacuum to give crude product. The crude 
product was further purified by silica gel column chromatography using ethyl acetate/ hexane 
(1/1, v/v) to give white wax like powder (70 %). The product was mixture of cis- and trans- 
isomers on carbamate bonds. 1H NMR (500 MHz, CDCl3): δ 6.56 (m, 1H), 6.02 (s, 1H), 5.28 (m, 
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2H), 4.66 (m, 1H), 4.12 (m, 5H), 3.38 (s, 4H), 3.01 (d, 3H), 2.88 (m, 3H), 2.12 (s, 3H), 2.06 (s, 
3H), 1.99 (s, 3H), 1.45 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 170.48, 170.17, 170.12, 169.47, 
166.58, 166.57, 92.56, 70.25, 69.19, 65.05, 61.76, 54.00, 53.43, 52.46, 49.46, 35.69, 29.70, 
28.39, 20.76, 20.74, 20.65, 20.59; HRMS-ESI (m/z): [M+Na]+ calculated for C24H38N6O12Na, 
625.2445; observed, 625.2433. 
Scheme 5.5 Synthetic route of HQ-NN-AAM (8)  
 
Synthesis of HQ-COOH (6). HQ-COOH was synthesized using similar route as reported 
before.21 Methyl sulfonic acid (40 mL) were heated to 70 °C. Methyl 3-methyl-2-butenoate (3.6 
g, 31.5 mmol) and trimethylhydroquinone (4.0 g, 26.3 mmol) were added under stirring. The 
mixture was stirred for another 90 min at 70 °C. The reaction was quenched by adding 500 mL 
of DI water and extracted with ethyl acetate three times. The organic phase was washed with 
water, saturated sodium bicarbonate, and brine. The crude product was recrystallized from 
chloroform and hexane to yield pure intermediate. The intermediate (3.0 g, 12.8 mmol) was then 
suspended in 150 mL of 10 % acetonitrile in water. N-bromosuccinimide (2.4 g, 13.4 mmol) 
dissolved in 40 mL of acetonitrile was added to the suspension slowly. The mixture was stirred 
at room temperature for 1 hour. The reaction mixture was extracted with ether (200 mL x 3) and 
organic phase was combined and dried. The solvent was evaporated to give yellow powder crude 
product. Pure HQ-COOH was obtained by recrystallizing in DCM/hexane. 1H NMR (500 MHz, 
CDCl3): δ 3.02 (s, 2H), 2.14 (s, 3H), 1.95 (q, 3H), 1.92 (q, 3H), 1.43 (s, 6H); 
13C NMR (125 
MHz, CDCl3): δ 190.83, 187.42, 177.94, 151.97, 142.95, 139.06, 138.41, 47.14, 37.95, 28.81, 




Synthesis of HQ-NN-Boc (7). HQ-COOH (6, 1.5 g, 6.0 mmol), Boc-NN (3, 0.94 g, 5.0 mmol), 
dicyclocabodiimide (DCC, 1.55 g, 7.5 mmol), and DMAP (61 mg, 0.5 mmol) were dissolved in 
50 mL of anhydrous DCM. The mixture was stirred at room temperature for 16 h. The mixture 
was filtered and filtrate was concentrated in vacuum. Pure product was obtained by silica gel 
column chromatography using ethyl acetate/ hexane (1/2, v/v) as eluent to get yellow oil. The 
product was mixture of cis- and trans- isomers on carbamate bonds. 1H NMR (500 MHz, 
CDCl3): δ 3.27-3.41 (m, 4H), 2.82-2.98 (m, 8H), 2.11 (m, 3H), 1.89-1.93 (m, 6H), 1.41-1.48 (m, 
15H); 13C NMR (125 MHz, CDCl3): δ 191.22, 187.66, 172.12, 155.64, 154.57, 143.23, 137.93, 
136.08, 79.49, 47.97, 46.72, 37.42, 35.03, 28.61, 28.47, 14.18, 14.12, 12.66, 12.59, 12.09; 
HRMS-ESI (m/z): [M+H]+ calculated for C23H37N2O5, 421.2702; observed, 421.2710. 
Synthesis of HQ-NN-AAM (8). HQ-NN-Boc (7, 400 mg, 0.95 mmol) were dissolved in 5 mL of 
DCM and added 5 mL of trifluoroacetic acid (TFA). The solution was stirred at room 
temperature for 2 h and the solvent was evaporated in vacuum. The crude product was re-
dissolved in 20 mL of anhydrous DCM. NB-O-AAM (4, 300 mg, 0.54 mmol), DIPEA (1.0 mL, 
excess amount), DMAP (10 mg, 0.08 mmol) were added to the reaction mixture. The reaction 
mixture was stirred at room temperature for 16 h. 10 mL of 1 M HCl was added to quench the 
reaction. The reaction mixture was extracted using DCM (100 mL x 3) and the organic phase 
was combined. The organic phase was washed with saturated NaHCO3 (150 mL x 3) and dried 
using anhydrous Na2SO4. The solvent was evaporated in vacuum to get crude product. Pure 
product was obtained after separation by silica gel column chromatography using ethyl 
acetate/hexane (1/1, v/v) as the eluent to get yellow powder. The product was a mixture of cis- 
and trans- isomers on carbamate bonds (75 % yield). 1H NMR (500 MHz, CDCl3): δ 6.56 (m, 
1H), 6.01 (m, 1H), 5.27 (m, 2H), 4.67 (m, 1H), 4.25 (m, 1H), 4.10 (m, 4H), 3.44 (m, 4H), 2.99 
(m, 8H), 2.02 (m, 18H), 1.42 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 191.19, 187.59, 172.47, 
170.44, 170.10, 169.47, 166.58, 154.42, 153.09, 143.00, 138.09, 136.60, 92.56, 70.14, 69.12, 
65.02, 61.79, 60.39, 52.47, 49.51, 48.16, 45.12, 37.65, 36.49, 33.63, 28.55, 21.06, 20.74, 20.59, 
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NMR SPECTRA OF NEW COMPOUNDS* 
 
A.1 NMR spectra of PAHAs in chapter 2. 
 
Figure A1. 1H NMR spectrum of poly(PheOCA) prepared with (BDI)Zn-1 (500 MHz, CDCl3, x 
axis: δ ppm). 
                                                 
* Part of this chapter is adapted from the publication: (1) Wang, R.; Zhang, J.; Yin, Q.; Xu, Y.; Cheng, J.*; Tong, 
R.*, “Controlled Ring-Opening Polymerization of O-Carboxyanhydrides Using β-Diiminate Zinc Catalyst.” Angew. 
Chem. Int. Ed. 2016, 55, 13010-13014. (2) Wang, R.; Cai, K.; Wang, H.; Yin, C.; Cheng, J. “A caged metabolic 




Figure A2. Homonuclear decoupled 1H NMR spectrum of poly(PheOCA) prepared with 
(BDI)Zn-1 (600 MHz, CDCl3, x axis: δ ppm). 
 
Figure A3. 13C NMR spectrum of poly(PheOCA) prepared with BDIZn-1 (125 MHz, CDCl3, x 




Figure A4. 1H NMR spectrum of poly(LacOCA) prepared with (BDI)Zn-1 (500 MHz, CDCl3, x 
axis: δ ppm). 
 
Figure A5. Homonuclear decoupled 1H NMR spectrum of poly(LacOCA) prepared with 




Figure A6. 13C NMR spectrum of poly(LacOCA) prepared with (BDI)Zn-1 (125 MHz, CDCl3, x 
axis: δ ppm). 
 
Figure A7. 1H NMR spectrum of poly(Ser(Bn)OCA) prepared with (BDI)Zn-1 (500 MHz, 




Figure A8. Homonuclear decoupled 1H NMR spectrum of poly(Ser(Bn)OCA) prepared with 
(BDI)Zn-1 (600 MHz, CDCl3, x axis: δ ppm). 
 
Figure A9. 13C NMR spectrum of poly(Ser(Bn)OCA) prepared with (BDI)Zn-1 (125 MHz, 




Figure A10. 1H NMR spectrum of poly(ManOCA) prepared with (BDI)Zn-1 (500 MHz, CDCl3, 
x axis: δ ppm). 
 
Figure A11. 13C NMR spectrum of poly(ManOCA) prepared with (BDI)Zn-1 (125 MHz, CDCl3, 




Figure A12. 1H NMR spectrum of poly(Tyr(allyl)OCA) prepared with (BDI)Zn-1 (600 MHz, 
CDCl3, x axis: δ ppm). (peak at 5.2 ppm is overlapped by a quartet (Ha) and a doublet (Hc)) 
 
Figure A13. Homonuclear decoupled 1H NMR spectrum of poly(Tyr(allyl)OCA) prepared with 
(BDI)Zn-1 (600 MHz, CDCl3, x axis: δ ppm). (peak at 5.2 ppm is overlapped by a singlet (Ha) 




Figure A14. 13C NMR spectrum of poly(Tyr(allyl)OCA) prepared with (BDI)Zn-1 (125 MHz, 
CDCl3, x axis: δ ppm). 
 
Figure A15. 1H NMR spectrum of poly(LacOCA) prepared with DMAP/ iPrOH (500 MHz, 




Figure A16. Homonuclear decoupled 1H NMR spectrum of poly(LacOCA) prepared with 
DMAP/ iPrOH (500 MHz, CDCl3, x axis: δ ppm). 
 
Figure A17. 1H NMR spectrum of poly(PheOCA) prepared with DMAP/ iPrOH (500 MHz, 




Figure A18. Homonuclear decoupled 1H NMR spectrum of poly(PheOCA) prepared with 
DMAP/ iPrOH (500 MHz, CDCl3, x axis: δ ppm). 
 
Figure A19. 1H NMR spectrum of poly(Ser(Bn)OCA) prepared with DMAP/ iPrOH (500 MHz, 




Figure A20. Homonuclear decoupled 1H NMR spectrum of poly(Ser(Bn)OCA) prepared with 
DMAP/ iPrOH (500 MHz, CDCl3, x axis: δ ppm). 
 
Figure A21. 13C NMR spectrum of poly(Ser(Bn)OCA) prepared with DMAP/ iPrOH (125 MHz, 




Figure A22. 1H NMR spectrum of poly(ManOCA) prepared with DMAP/ iPrOH (500 MHz, 
CDCl3, x axis: δ ppm). 
 
Figure A23. 13C NMR spectrum of poly(ManOCA) prepared with DMAP/ iPrOH (125 MHz, 




A.2 NMR spectra of compounds in chapter 5: 
 
Figure A24. 1H NMR spectrum of Et-O-AAM (1) in CDCl3 (500 MHz, x axis: δ ppm). 
 




Figure A26. 1H NMR spectrum of Bu-N-AAM (2) in CDCl3 (500 MHz, x axis: δ ppm). 
 




Figure A28. 1H NMR spectrum of Boc-NN (3) in CDCl3 (500 MHz, x axis: δ ppm). 
 




Figure A30. 1H NMR spectrum of NB-O-AAM (4) in CDCl3 (500 MHz, x axis: δ ppm). 
 




Figure A32. 1H NMR spectrum of Boc-NN-AAM (5) in CDCl3 (500 MHz, x axis: δ ppm). 
 




Figure A34. 1H NMR spectrum of HQ-COOH (6) in CDCl3 (500 MHz, x axis: δ ppm). 
 




Figure A36. 1H NMR spectrum of HQ-NN-Boc (7) in CDCl3 (500 MHz, x axis: δ ppm). 
 




Figure A38. 1H NMR spectrum of HQ-NN-AAM (8) in CDCl3 (500 MHz, x axis: δ ppm). 
 
Figure A39. 13C NMR spectrum of HQ-NN-AAM (8) in CDCl3 (125 MHz, x axis: δ ppm). 
 
 
